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Intracellular zinc release triggered by oxidative injury leads to cellular K+ efflux and neuronal 
apoptosis. Low intracellular K+ enables protease and nuclease activation during cell death 
processes.  Our laboratory has demonstrated that the reduction in cytosolic K+ occurs via zinc-
dependent phosphorylation of Kv2.1 by Src kinase and p38 MAPK, leading to the insertion of 
new Kv2.1 channels into the plasma membrane of dying neurons. As calcium dyshomeostasis is 
also observed in many models of neuronal injury, I tested the hypothesis that zinc- and Kv2.1-
mediated apoptosis also depended on increased intracellular calcium. I observed that oxidant 
exposure triggered release of calcium from the endoplasmic reticulum, which led to the 
activation of   the  calcium/calmodulin-dependent  protein  kinase II  (CaMKII).  Molecular or 
pharmacological inhibition of CaMKII prevented both the oxidant-induced K+ current 
enhancement and, importantly, subsequent cell death. Further, I found that CaMKII regulated 
apoptosis by its direct association with the SNARE protein syntaxin, with syntaxin mediating the 
plasma membrane insertion of Kv2.1 via enhanced association with the phosphorylated channel. 
As such, Kv2.1/syntaxin binding was enhanced under conditions that promoted apoptosis, and 
inhibiting CaMKII prevented this interaction. Moreover, expression of a Kv2.1-derived peptide 
containing the channel’s c-terminal syntaxin binding site (C1a) was also sufficient to disrupt 
Kv2.1/syntaxin binding, preventing both the oxidant-induced K+ current enhancement and 
downstream apoptosis. Together, these findings support a novel role for calcium and CaMKII in 
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an established zinc-mediated injury cascade. Further, they suggest that the metals work in 
concert to elicit the pro-apoptotic Kv2.1 channel activity necessary for oxidative stress-induced 
apoptosis.  Finally, disruption of the pro-apoptotic syntaxin/Kv2.1 interaction may lead to novel 
therapeutic approaches for neurological disorders associated with oxidant-induced signaling. 
 vi 
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1.0  INTRODUCTION 
1.1 OXIDATIVE STRESS: FOCUS ON AGING 
Brain aging is marked by gradual, general cellular dysfunction occurring as a result of structural, 
chemical, and genetic alterations that manifest themselves as cognitive decline, albeit with great 
variability among individuals. While these changes are a normal and unavoidable part of the life 
cycle of neurons, aging itself is also a risk factor for a number of late-life neurodegenerative 
disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral 
sclerosis (ALS). Although the molecular underpinnings of age-related neuropathology have not 
been completely resolved, one recurring explanation for the alterations observed with age, which 
has been revisited repeatedly for nearly 50 years, is the free radical theory of aging. This theory 
posits that the deleterious cellular changes that occur during aging and cognitive decline can be 
attributed in part to a continuous deregulation of intracellular reactive oxygen species (ROS) 
production over time (Harman, 1965), a phenomenon usually referred to as oxidative stress. 
Although this theory has been modified slightly in more recent years (Beckman and Ames, 
1998), oxidative modifications caused by chronic ROS production remain recognized as a 
critical constituent of numerous neuropathological processes, and therefore represent a vitally 
important topic in the field of neurodegeneration research.  
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In the brain, ROS are produced as a physiological consequence of the normal oxidative 
processes related to cellular signaling, metabolism, and homeostasis (Lander, 1997; D’Autreaux 
and Toledano, 2007). Further, in addition to their presence merely as a passive byproduct of 
these processes, ROS also play an important and active role in a number of physiological cellular 
functions including gene expression, long-term potentiation, and the immune response (e.g. Sen 
and Packer, 1996; Knapp and Klann, 2002). As such, ROS are an integral component of a 
neuron’s intracellular milieu. However, while ROS are important for normal cellular processing 
under certain circumstances, they are more widely recognized for their deleterious role in the 
initiation and propagation of neuronal injury. Namely, unregulated, excess production of these 
reactive intermediates during oxidative stress can have strong toxic effects on proteins, lipids, 
and nucleic acids.  Moreover, ROS are also capable of triggering injurious signaling cascades 
that ultimately result in the demise of neurons by apoptosis or other forms of cell death 
(Beckman and Crow, 1993). Oxidative stress-induced cellular dysfunction can also exacerbate 
ROS production downstream of the initial insult, thereby maintaining the oxidative stress state in 
a self-propagating injury cycle that can lead to neuronal death if left unchecked (Beckman and 
Ames, 1998; Finkel and Holbrook, 2000).  
1.2 ROS GENERATION AND MAINTENANCE OF PROPER OXIDATIVE 
HOMEOSTASIS 
Under normal circumstances, ROS are produced primarily as a limited byproduct of oxidative 
phosphorylation during the formation of ATP, which occurs via a set of redox reactions in 
mitochondria (Chance et al., 1979). Mitochondrial dysfunction, however, is commonly 
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associated with neural injury cascades, and thus, in addition to their role in physiological ROS 
generation, mitochondria are regarded as one of principal producers of oxidative intermediates in 
pathological conditions. ROS themselves can also contribute to mitochondrial dysfunction either 
indirectly through the initiation of toxic signaling cascades that target mitochondria, or through 
direct damage to mitochondrial DNA (Richter et al., 1988; Esposito et al., 1999; Melov et al., 
1999; Wallace, 2005). In addition to mitochondria, other intracellular generators of reactive 
metabolites contribute to oxidative stress during aging, including NADPH oxidases, nitric oxide 
synthases (NOSs), lipoxygenases (LOXs), and peroxisomes. Extraneuronal sources of ROS such 
as microglia, a non-neuronal, supporting cell involved in CNS immune responses, as well as 
exogenous stimuli such as UV light, ionizing radiation, and environmental toxins, also contribute 
to age-related neuronal dysfunction. 
The brain, despite representing only 2% of the body weight, receives 15% of the cardiac 
blood output and accounts for 20% of the body’s total oxygen consumption. The pronounced 
oxidative metabolism present in the brain results in a large generation of ROS during normal 
function. Neurons contain a system of enzymes and antioxidants to detoxify ROS after they are 
produced, as well as mechanisms to repair oxidant-induced damage once it has occurred; still, 
neurons become highly vulnerable to ROS-mediated damage when they are not able to adapt to 
ROS overproduction during times of stress. Therefore, oxidative stress occurs either from an 
overproduction of ROS, a deficiency in the antioxidant response, or both. Oxidative stress can 
thus be further defined as a condition in which the number of ROS produced surpasses a 
threshold over which they can no longer be adequately neutralized (Halliwell, 1992). Further, the 
deleterious consequences of oxidative stress tend to be exacerbated in the aged brain due to the 
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combination of increased oxidant production (Gabbita et al., 1997), along with decreased ability 
to detoxify ROS and repair oxidatively stressed tissue (Barnett and King, 1995).  
While it is not entirely surprising that cells become less able to combat the increased 
concentrations of injurious oxidative intermediates as they age, oxidative stress does not occur in 
isolation, and thus is not solely responsible for the toxic cellular processes observed during age-
related neuropathology. Of course, many interrelated dysfunctional cellular processes coincide to 
lead to the immense cell loss observed during AD and other neurodegenerative disorders. One 
such factor, which appears to be inextricably linked to oxidative stress damage in neurons, is 
zinc dyshomeostasis. Indeed, much like uncontrolled ROS production can have profoundly 
detrimental effects on neurons during aging, dyshomeostasis of intracellular zinc is also a crucial 
determinant of the fate of neurons in the aged brain.  
1.3 ZINC IN THE BRAIN 
Zinc is a ubiquitous trace element found throughout the body, including the brain, with particular 
abundance in the auditory brainstem, olfactory bulb, amygdala, hippocampus, and cortex 
(Frederickson et al., 1988; Weiss et al., 2000; Frederickson et al., 2000; Sekler et al., 2002). The 
cation plays a pivotal role in a multitude of cellular processes including neurotransmission, 
enzymatic activity, gene regulation, and structural maintenance and stabilization of proteins 
(Vallee and Falchuk, 1993; Choi and Koh, 1998; Frederickson et al., 2005). Due to its 
widespread function within neurons, intracellular zinc concentrations are tightly regulated, as 
proper homeostasis of the metal is critical in the maintenance of normal cellular processing. 
Indeed, zinc binds with high affinity to a very large number of proteins: roughly 3000 human 
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genes, or 10% of the genome, have been identified as encoding for zinc-binding proteins 
(Andreini et al., 2006). While the majority (80-90%) of the zinc present in the brain is found 
bound to metal-binding proteins, the remaining fraction is packaged within synaptic vesicles of a 
large sub-population of excitatory neurons. This synaptic or vesicular zinc is released in an 
activity-dependent manner, and can modulate the activation of several neurotransmitter 
receptors, including NMDA, AMPA, GABAA and glycine receptors (for review see Smart et al., 
2004; Paoletti et al., 2009; Sensi et al., 2011), as well as voltage-dependent ion channels (e.g. 
Grauert et al., 2013). In addition, synaptically released zinc interacts with a specific zinc-sensing 
metabotropic receptor (mZnR/GPR39) to modulate synaptic activity through its effect both on 
the outward chloride transporter KCC2, and on the synthesis of 2-arachidonoylglycerol, an 
endocannabinoid that modulates probability of presynaptic neurotransmitter release (Besser et 
al., 2009; Chorin et al., 2011; Saadi et al., 2012; Perez-Rosello et al., 2013). 
1.4 ZINC TOXICITY 
It is well established that zinc exposure is toxic to neurons both in vitro (Yokoyama et al., 1986; 
Choi et al., 1988) and in vivo (Lees et al., 1990; Cuajungco et al., 1996). The overall 
concentration of the metal within the brain is ~150 µM, although the vast majority of 
intracellular zinc is normally rendered immobile through buffering by cytosolic metal-binding 
proteins and sequestration into organelles (Sensi et al., 2011). However, when neurons are 
damaged, as occurs during oxidative stress, bound intracellular zinc can be released into the 
cytosol, where it then triggers a number of detrimental signaling processes including those that 
lead to further ROS production, marking the start of a positive feedback loop involving 
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intracellular zinc release and ROS generation. Synaptic zinc has also been associated with 
neuronal dysfunction by its transfer from over-active presynaptic zinc-containing neurons to 
postsynaptic cells via calcium-permeable channels, including, but not limited to a sub-class of 
AMPA receptors (Weiss et al., 1993; Koh et al., 1996; Sensi et al., 2000). While proper zinc 
homeostasis is critical at all stages of life, the delicate balance required to keep zinc levels in 
check appears to be particularly precarious in the aged brain. This is likely due to the fact that, as 
mentioned earlier, relative ROS levels increase as we age, and intracellular zinc fluxes appear to 
be very susceptible to perturbation by ROS. Indeed, zinc has been proposed as being a critical 
link between oxidative stress and aging (Frazzini et al., 2006). To begin to understand the mutual 
regulation between intracellular zinc release and ROS generation, it is first necessary to review 
what is currently known about how zinc is maintained within neurons and, more importantly, 
how the metal is liberated from metal-binding proteins during oxidative injury. 
1.5 ZINC DYSHOMEOSTASIS AND NEURONAL INJURY 
While the largest concentration of zinc in the brain is bound to intracellular metal-binding 
proteins, there is a second pool, localized to synaptic vesicles of glutamatergic neurons, which 
constitutes 10-20% of the total concentration of the metal in neurons (Frederickson, 1989). In 
early studies, it was thought that cytoplasmic influx of synaptically released zinc, referred to as 
“translocation,” was the primary source of toxic intracellular zinc increases during neuronal 
injury. This idea, however, was inconsistent with later studies of mice that lacked the gene 
encoding ZnT3, the transporter responsible for loading zinc in synaptic vesicles (Cole et al., 
1999). Despite the fact that these animals were devoid of vesicular zinc, increased intracellular 
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concentrations of the metal and subsequent cell death still occurred, even in the apparent absence 
of zinc translocation from pre- to post-synaptic neurons (Lee et al., 2000). Thus, these findings 
strongly suggested that other sources of zinc release could also be contributing to the increased 
intracellular levels of the metal observed during neuronal injury. Since then, it has become 
increasingly clear that increased cytosolic zinc resulting from liberation from intracellular stores 
can be highly toxic during oxidative and other types of neuronal injury. 
1.6 INTRACELLULAR SOURCES OF ZINC RELEASE 
One of the main intracellular zinc binding proteins within neurons is metallothionein III (MT 
III). MT III is one member of a family of thiol-rich metal-binding proteins, and is the primary 
isoform found in neurons (Hidalgo et al., 2001). Close to a third of the 61-68 amino acids that 
constitute MT III are cysteine residues, cumulatively capable of binding up to seven zinc ions via 
their thiol side chains. Other MT isoforms have been shown to bind the seven zinc ions with 
varying affinities, supporting a role for MTs in the dynamic regulation of zinc levels dictated by 
the needs of the cell at any given time (Krezel and Maret, 2007). In this capacity, MT III acts as 
an intracellular regulator of zinc homeostasis via coordinated binding and release of the metal. 
Due to the very low redox potential of its thiols (-366 mV), MT III is readily oxidized, even by 
relatively mild oxidants. This oxidation results in the liberation of the bound zinc ions (Maret 
and Vallee, 1998); thus, while zinc itself is redox-inactive, its association with MT III makes it 
extremely susceptible to changes in cellular redox state. The release of zinc from MT III by 
oxidants causes a substantial increase in intracellular zinc concentration, and this single event has 
been established as a powerful inducer of neuronal injury (Aizenman et al., 2000). 
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Once zinc has been liberated from MT III, it can have numerous adverse effects on 
neuronal function. As mentioned previously, mitochondria are the primary producers of ROS in 
neurons, and zinc plays a critical role in the regulation of mitochondrial dysfunction and ROS 
generation during neuronal injury. Following intracellular liberation of the cation, mitochondria 
have been shown to take up cytoplasmic free zinc through both the calcium uniporter as well as 
through an independent import mechanism that has yet to be identified (Sensi et al., 2003; 
Malaiyandi et al., 2005). Once sequestered in the organelle, zinc can inhibit the electron transport 
chain, thereby reducing mitochondrial membrane potential, which subsequently leads to an 
increase in ROS generation (Sensi et al., 1999; Dineley et al., 2005; Dietz et al., 2008; 
Medvedeva et al., 2009). Interestingly, MT III has also been shown to translocate to 
mitochondria and release zinc ions within the mitochondrial intramembranous space, suggesting 
a dynamic regulation of zinc homeostasis by the combined actions of MT III and mitochondria 
(Ye et al., 2001). In addition to the MT III-mediated zinc effects on mitochondria, the organelle 
itself is shown to contain an independent store of zinc, which can be released during injury 
(Sensi et al., 2003). In that study, co-treatment with the thiol oxidant 2,2’-dithiodipyridine 
(DTDP) and the mitochondrial protonophore FCCP resulted in a greater increase in cytosolic 
zinc than was observed by treatment with either drug alone, which the authors attributed to the 
existence of distinct stores of the metal that can each be liberated by unique injurious stimuli. 
Thus, it appears that mitochondria and MT III work in tandem to dynamically regulate 
intracellular availability of the cation. However, while it is known that both MT III and 
mitochondria can modulate zinc levels, additional work is still needed to reveal the specific 
contributions of each pool to the propagation of pro-death cascades following various forms of 
neuronal injury. 
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1.7 ZINC-MEDIATED ROS GENERATION IN VITRO 
In addition to triggering ROS production from mitochondria, zinc has also been found to be 
involved in injurious oxidant generation from a number of extra-mitochondrial sources. 
Interestingly, ROS generation and intracellular zinc release appear to be common constituents of 
a number of toxic signaling pathways in neurons. One of the better-studied zinc-mediated 
apoptosis cascades involves exogenous ROS-triggered zinc liberation and subsequent generation 
of endogenous oxidative intermediates. Specifically, cytosolic accumulation of MT III-liberated 
zinc can be caused by exposure to the oxidant DTDP or peroxynitrite (ONOO-), a physiological 
oxidant generated by the reaction between free radicals nitric oxide (NO) and superoxide 
(Beckman et al., 1990). The increase in intracellular zinc then promotes production of superoxide 
from the enzyme 12-lipoxygenase (12-LOX), loss of mitochondrial membrane potential, and 
activation of Src kinase and p38 MAPK, the latter by upstream MAPKKK apoptosis signal-
regulating kinase 1 (ASK-1; Aizenman et al., 2000; McLaughlin et al., 2001; Zhang et al., 
2004a; Aras and Aizenman, 2005). Once activated, Src and p38 directly phosphorylate the 
voltage gated, delayed rectifier Kv2.1 channel at residues Y124 and S800, respectively, to trigger 
the insertion of new channels into the plasma membrane, leading to enhanced K+ efflux and 
consequent reduction in intracellular K+, caspase activation, and finally, apoptotic cell death 
(Aizenman et al., 2000; McLaughlin et al., 2001; Redman et al., 2007; Redman et al., 2009). The 
oxidant-induced, zinc-initiated signaling cascade is accompanied by concomitant intracellular 
calcium release from the endoplasmic reticulum (ER), and downstream CaMKII activation, 
which is necessary for the exocytotic introduction of Kv2.1 channels into the plasma membrane 
(McCord and Aizenman, 2013). Exposure to NO or activated microglia-derived ONOO- can also 
initiate this zinc- and Kv2.1-dependent apoptosis cascade (Bossy-Wetzel et al., 2004; Knoch et 
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al., 2008), and NO exposure has also been shown to lead to cytosolic zinc accumulation in 
hippocampal neurons in vivo (Cuajungco and Lees, 1998). 
Independently, NO, in combination with depletion of the antioxidant glutathione, was 
shown to activate 12-LOX, which resulted in cell death of neuronal cultures (Canals et al., 2003). 
While this study didn’t investigate the role of intracellular zinc release in this process, based on 
the injurious stimulus used and the downstream effects observed, these findings lend further 
support to the notion that various stimuli could trigger a common zinc-mediated injury cascade. 
Additionally, a number of studies have reported cell death following zinc-dependent activation 
of NADPH oxidase and nitric oxide synthase (NOS), which are the enzymes responsible for 
generating superoxide and NO, respectively (Noh and Koh, 2000; Kim and Koh, 2002; Kumar et 
al., 2012). While these reports focused on the effect of exogenous zinc exposure, considering the 
close relationship between intracellular zinc release and ONOO-, as well the ability of 
exogenously applied zinc to enter neurons, it is not unreasonable to assume that intracellular zinc 
stores may also play a role in NADPH oxidase and NOS co-activation. Taken together, it appears 
that many of the components involved in injurious mitochondrial and extra-mitochondrial ROS 
production, as well as the downstream processes triggered by ROS, all seem to share a common 
association with intracellular zinc release. 
1.8 ZINC IN HUMAN NEURODEGENERATION: SPOTLIGHT ON ALZHEIMER’S 
DISEASE 
The experimental findings summarized thus far illustrate the concept that intracellular zinc 
release is a common toxic event in certain forms of oxidant-induced neuronal apoptosis. As 
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oxidative stress is a major contributor to brain aging and age-related pathology, it is feasible that 
zinc dyshomeostasis may also be involved in disorders associated with aging neurons 
(Mocchegiani et al., 2005). While the exact role of intracellular zinc in the pathophysiology of 
neurodegenerative disorders is not entirely clear, there is a growing body of work implicating the 
metal in age-related neurodegeneration. Oxidative stress-induced cell death is common between 
Alzheimer’s disease, Parkinson’s disease, and ALS, as well as many other neurological disorders 
(Behl et al., 1994; Mecocci et al., 1994; Smith et al., 1998; Dexter et al., 1989; Olanow, 1993; 
Wiedau-Pazos et al., 1996). However, because the literature on the role of metals in AD is 
extensive, this review will focus only on zinc deregulation during AD in an attempt to paint a 
more cohesive picture demonstrating the fact that this metal, when unregulated, can wreak havoc 
on the health of neurons in an aging brain.  
AD is characterized by several pathological hallmarks including amyloid plaque deposits, 
aggregation of neurofibrillary tangles (NFTs) composed of the protein tau in a 
hyperphosphorylated form, and synaptic loss and neuronal deterioration, predominantly through 
apoptosis (Hanger et al., 2009). Amyloid plaques are comprised primarily of beta amyloid (Aβ), 
a ~40 amino acid long peptide generated through cleavage of the amyloid precursor protein 
(APP; Kang et al., 1987). Accumulation of Aβ during AD has been shown to cause neuronal 
apoptosis both in vitro and in vivo (Kowall et al., 1992; Loo et al., 1993). Additionally, AD and 
oxidative stress appear to go hand in hand, with ROS production being both a cause and 
consequence of Aβ aggregation (Markesbery, 1997; Butterfield et al., 2001). 
 The toxic role of zinc dyshomeostasis has become an important topic in the study of AD 
pathology (Bush and Tanzi, 2008; Greenough et al., 2013). However, the majority of this work 
has focused on how synaptically released zinc contributes to AD-related neuronal dysfunction 
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and death, and studies to characterize the effects of changes in endogenous intracellular zinc 
levels remain sparse. Still, the few reports that have examined this source of zinc support a toxic 
role for increased intraneuronal zinc in AD. One of the first studies to consider intracellular zinc 
deregulation in AD brains found that not only did the metal localize to extracellular amyloid 
plaque deposits, but that cytosolic zinc levels were increased as well, particularly in neurons 
exhibiting intracellular neurofibrillary tangles (Suh et al., 2000). More recently, the effect of 
oxidative stress on intracellular zinc mobilization was determined in neurons derived from 3xTg-
AD mice, a triple transgenic AD mouse model that exhibits both Aβ and tau pathology. 
Importantly, this study found that intracellular zinc levels were substantially higher in 3xTg-AD 
neurons than in control cells following exposure to DTDP (Sensi et al., 2008). Thus, while 
studies of cytosolic zinc changes in AD are still in their relative infancy, these results suggest 
that intracellular zinc liberation could be critical for the progression of AD pathology, and that 
these effects appear to be mediated by the metal’s interaction with ROS.  
Zinc plays an important role in Aβ aggregation, as the peptide has been shown to bind to 
the metal (Bush et al., 1994a). Additionally, not only does zinc exposure induce the aggregation 
of amyloid plaques (Bush et al., 1994b; Esler et al., 1996), but the plaques themselves are rich in 
zinc, as well as copper. It is thought that Aβ is primarily responsible for inducing a state of 
oxidative stress during AD through direct production of oxidants (Markesbery, 1997; Huang et 
al., 1999; Butterfield et al., 2001), as well as through activation of microglia and subsequent 
generation of ONOO- (Goodwin et al., 1995; Meda et al., 1995; McDonald et al., 1997; 
Sturchler-Pierrat, 1997; Weldon et al., 1998). As mentioned earlier, ONOO- production 
originating from both neurons and microglia appears to be a key trigger of zinc-dependent 
neuronal apoptosis (Zhang et al., 2004a; Knoch et al., 2008). Further, hydrogen peroxide, an 
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oxidant produced by Aβ directly (Huang et al., 1999), can cause the release of zinc from MT III, 
subsequently causing aggregation of Aβ. Although it was not specified if MT III was localized 
intra- or extracellularly, Aβ aggregates induced by endogenous zinc release were 
morphologically distinct from those induced by exogenous zinc application, suggesting a unique 
role for different zinc pools during AD (Durand et al., 2010). Interestingly, chelation of the 
cation facilitates the dissolution of these toxic deposits both in vitro (Huang et al., 1997) and in 
post-mortem AD brain tissue (Cherny et al., 1999). Unlike humans, aged mice and rats do not 
express Aβ in an aggregated form, and as such, do not exhibit the related neuropathology. 
Intriguingly, one notable difference between human and rodent Aβ is the peptide’s ability to bind 
zinc, with human Aβ exhibiting a much higher affinity for the metal (Huang et al., 2004). Thus, 
it is tempting to speculate that zinc could be directly responsible for the characteristic toxic 
aggregation of Aβ observed in AD patients, although more work is needed to definitively 
confirm this. 
While it is known that both exogenous and synaptically released zinc induce Aβ 
aggregation (Bush et al., 1994b; Deshpande et al., 2009), it appears that increased intracellular 
zinc may also play a role in this process, although conclusive work demonstrating this has yet to 
be undertaken. Aβ was originally identified as solely being localized extracellularly; however, 
other studies have shown that Aβ is also found in the cytoplasm of neurons (Turner et al., 1996; 
Wild-Bode et al., 1997; Gouras et al., 2000). Interestingly, a number of studies have shown that 
intracellular Aβ (Aβi) formation precedes the appearance of extracellular Aβ, lending support to 
the hypothesis that an intracellular pool of the peptide is a prerequisite for extracellular plaque 
formation (Walsh et al., 2000; Wirths et al., 2001). However, further work is required to clarify if 
Aβi plays a causative role in the formation of extracellular plaques, and if intracellular zinc 
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release promotes the induction of Aβi. Nonetheless, in support of a role for cytosolic zinc, Aβi 
accumulation has been shown to correlate with microglial activation, increased NO production, 
and p38 activation (Rodrigo et al., 2004; Takuma et al., 2009), all of which are events that have 
previously been linked to pro-apoptotic intracellular zinc release (McLaughlin et al., 2001; 
Bossy-Wetzel et al., 2004; Knoch et al., 2008). Further, Aβi accumulation can be triggered by 
exposure to oxidants (Ohyagi et al., 2000), and its accumulation has been shown to be localized 
to mitochondria, which also contain zinc (Rodrigo et al., 2004), and to the ER (Hartmann et al., 
1997), an organelle recently shown to be involved in zinc- and Kv2.1-dependent neuronal 
apoptosis (McCord and Aizenman, 2013). Zinc has been shown to be localized to the ER (Stork 
and Li, 2010; Taylor et al., 2012) and released following OONO- exposure (Lin et al., 2013), 
further bolstering a potential role for the cation in Aβi accumulation within the ER. Taken 
together, it is reasonable to hypothesize that intracellular zinc release could be an important 
factor in the accumulation of Aβ within neurons observed during AD. 
Despite the presence of zinc in Aβ and evidence for its critical role in the aggregation of 
this toxic peptide, not all findings support a deleterious role for zinc in AD. In fact, exposure to 
low micromolar concentrations of the metal has been shown to destabilize Aβ aggregation and 
be protective against Aβ-induced toxicity (Garai et al., 2007). However, while low levels of zinc 
may protect neurons from Aβ-mediated damage, exposure to higher concentrations of the metal 
are toxic under otherwise equivalent conditions (Lovell et al., 1999). Like the effect of 
exogenous zinc on AD-related toxicity, the concentration of endogenous zinc within AD brains 
is also a contentious issue, although discrepancies in these studies could very well be a result of 
differences in the conditions under which the measurements were taken. Nonetheless, it appears 
that although some studies have reported decreased zinc levels in certain regions of AD brains 
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(Danscher et al., 1997; Panayi et al., 2002), the overall trend supports an increase in cerebral zinc 
during AD (Thompson et al., 1988; Deibel et al., 1996; Danscher et al., 1997; Religa et al., 
2006). Indeed, zinc chelation has proven to be neuroprotective against Aβ-mediated toxicity (Lee 
et al., 2004). Moreover, high concentrations of the metal have been localized to amyloid plaques 
and neuropil derived from AD brains (Constantinidis, 1990; Suh et al., 2000; Lovell et al., 1998), 
further supporting a role for increased zinc in brain areas relevant to AD pathology. Aβ-localized 
zinc has also been shown to contribute to AD-related damage via its effect on toxic iron 
accumulation (Duce et al., 2010). During AD, increases in intracellular iron can exacerbate 
oxidative stress and contribute to tau aggregation (Bartzokis et al., 1994; Smith et al., 1997; 
Yamamoto et al., 2002). Recently, APP was shown to possess ferroxidase activity that 
contributed to iron export and a reduction in oxidative stress in a mouse model of AD. APP 
ferroxidase activity was inhibited by zinc, and was negatively correlated with increased Aβ 
accumulation, suggesting that the zinc originated from within amyloid plaques (Duce et al., 
2010). Aβ pathology can also influence the activity of certain kinases that have been closely 
associated with zinc deregulation and neuronal injury. Namely, numerous studies have reported 
increased phosphorylation of p38 in AD brains (Hensley et al., 1999; Zhu et al., 2000; Zhu et al., 
2001; Pei et al., 2001; Sun et al., 2003), which is also required for zinc-mediated neuronal 
apoptosis (McLaughlin et al., 2001). Additionally, ASK-1, the upstream MAPKKK of p38, has 
been linked to AD-related toxicity. Specifically, Aβ-mediated ROS production led to activation 
of ASK-1 and downstream cell death in PC12 cells and cortical neurons (Kadowaki et al., 2005). 
Thus, many of the pathological changes that take place during AD appear to be very similar to 
those observed in injury related to oxidant-induced zinc liberation and downstream apoptosis. 
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Similar to Aβ, zinc can also directly bind to tau to facilitate aggregation of the protein 
into NFTs (Mo et al., 2009). Like the bimodal regulation of Aβ-induced toxicity, modulation of 
tau by exogenous zinc also appears to be concentration-dependent, with lower concentrations of 
the metal causing a decrease in phospho-tau, while higher levels cause an increase (Boom et al., 
2009). Although these findings were based on exogenously applied zinc, the authors concluded 
that because tau accumulates intracellularly, the observed effect was likely due to translocation 
of exogenous zinc into the cytosol. Thus, while the effect of endogenous intracellular zinc 
release was not investigated, these studies nonetheless support a potential role for intracellular 
liberation of the cation in the regulation of tau during AD. Further support for this idea comes 
from evidence for accumulation of zinc predominantly within neurons that display NFTs (Suh et 
al., 2000). As mentioned previously, hyperphosphorylation of tau is required for its aggregation 
into NFTs, and many of the kinases involved in the zinc- and Kv2.1-mediated apoptosis cascade 
described previously also phosphorylate tau. Specifically, tau can be directly phosphorylated by 
both p38 (Reynolds et al., 1997) and CaMKII (Litersky et al., 1996). Further, exogenous zinc 
application can trigger Src kinase-dependent inactivation of PP2A, the primary phosphatase 
responsible for dephosphorylating tau (Liu et al., 2005; Liu et al., 2008). As mentioned earlier, 
zinc-dependent Src activity is also responsible for phosphorylating Kv2.1 channels prior to their 
insertion into the plasma membrane during to apoptosis (Redman et al., 2009). 
1.9 ZINC AND AUTOPHAGIC DYSFUNCTION  
Autophagy is a catabolic system used within cells to clear dysfunctional or unused proteins and 
macromolecules before they cause damage to neurons. Degradation of malfunctioning cellular 
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components during autophagy occurs in lysosomes, which are acidic organelles containing 
hydrolase enzymes that facilitate the decomposition process. Autophagy is important in the 
clearance of protein aggregates (Johansen and Lamark, 2011), and autophagic deregulation has 
come to be regarded as a key occurrence in AD-related pathology (Cuervo, 2008; Nixon and 
Yang, 2011). It has been suggested that cell death can result from oxidative stress-induced 
accumulation of Aβ within lysosomes, leading to lysosomal membrane permeabilization (LMP) 
and subsequent release of Aβ and other toxic molecules into the cytosol (Zheng et al., 2009). In 
addition to toxicity caused by LMP, reduced autophagy, which has been observed in AD, can 
also lead to cell death due to a buildup of damaged molecules that would otherwise be degraded. 
In this scenario, decreased autophagy can be toxic to neurons independently of the effects of 
LMP. While this area of AD research is still relatively new, zinc also appears to play an 
important role in lysosomal dysfunction triggered by oxidative stress. Namely, oxidant exposure 
has been shown to cause an accumulation of zinc within lysosome-derived vesicles, as well as 
within the cytosol itself, leading to apoptosis of hippocampal neurons. Further, apoptosis was 
prevented by the zinc chelator TPEN, demonstrating that the increase in cytosolic zinc was 
responsible for the observed toxicity (Hwang et al., 2008). 
Zinc deregulation during autophagic dysfunction has also been shown to have clinical 
significance. Administration of the prototype AD drug clioquinol can cause a reduction of tau 
and Aβ, as well as an improvement in cognitive performance (Regland et al., 2001; Ritchie et al., 
2003).  The effect of clioquinol on Aβ aggregation was initially thought to occur because of the 
drug’s ability to chelate zinc (Cherny et al., 2001). However, more recent work revealed that 
clioquinol actually functions by acting as an ionophore to increase influx of zinc into neurons 
from the extracellular space, which can then induce autophagy in neurons and astrocytes (Park et 
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al., 2011). Specifically, this study found that zinc localized to autophagic machinery (autophagic 
vacuoles, autolysosomes, and lysosomes), and was necessary for the clioquinol-induced 
clearance of accumulated huntingtin protein, which aggregates in Huntington’s disease. Thus, it 
appears that clioquinol may be important in degrading the Aβ and tau aggregates observed in 
AD, in part through its effect on extra- and intracellular zinc levels. However, this same study 
also showed that clioquinol caused zinc-dependent cell death in cortical neurons, although this 
experiment was not performed in the presence of Aβ or under other conditions that would mimic 
zinc levels or the overall cellular environment manifested in AD, and it is thus difficult to deduce 
the effect of clioquinol on neuronal viability during AD from this study alone. 
Both abnormally increased and decreased autophagy can be detrimental to neurons 
depending on the circumstances in which it takes place. The studies summarized here underscore 
the complex nature of the role of zinc in regulating autophagic dysfunction. Indeed, it appears 
that changes in intracellular zinc levels can dictate if autophagy will adopt a pro-death or pro-
survival function (Lee and Koh, 2010). As zinc dyshomeostasis can be observed both 
extracellularly and intracellulary during AD, much work remains to acquire a better 
understanding of the delicate balance of zinc that underlies normal cellular function, and at 
exactly what point metal-regulatory processes go awry to propagate the pathological effects 
observed during neurodegeneration. 
1.10 MT III AND NEURODEGENERATION 
As mentioned previously, MT III is one of the primary zinc-binding proteins within neurons, and 
therefore plays an integral role in maintaining homeostasis of the metal. In contrast to MT I and 
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MT II, which are normally induced by increased levels of free metals within cells, MT III is 
constitutively expressed. Knockdown of MT III can lead to increased oxidant-triggered 
intracellular zinc levels, while overexpression of the protein substantially reduces the amount of 
zinc detected within neurons following oxidant exposure (Aras et al., 2009). Interestingly, 
numerous independent studies have reported downregulation of MT III during AD (Uchida et al., 
1991; Tsuji et al., 1992; Yu et al., 2001). While these studies did not directly measure the effect 
of reduced MT III expression on intracellular zinc levels, they suggest that increased intracellular 
zinc concentration due to a reduction in MT III expression could be relevant to the pathological 
effects observed during the progression of the disease. Others, looking at the molecular 
consequences of changes in MT III during AD have shown that exogenous MT III exposure 
prevents the accumulation of Aβ and rescues neurons from Aβ-induced cell death (Irie et al., 
2001), supporting a beneficial role of MT III through the sequestration of extracellular zinc. 
Along these lines, MT III has been suggested to be secreted by cells in the brain, albeit by not 
well-defined pathways (Chung and West, 2004; Manso et al., 2011). Seemingly paradoxically, a 
few studies have reported increased MT III expression in AD (Zambenedetti et al., 1998; 
Carrasco et al., 1999), although investigations describing this phenomenon are much less 
common than those reporting decreased MT III. Further, MT III can act as both an acceptor and 
a donor of zinc, and thus changes in MT III expression could have different effects depending on 
the cellular environment and redox state within neurons. Knockdown of MT III in astrocytes has 
also been shown to lead to a decrease in the degradative capacity of lysosomes (Lee et al., 2010), 
consistent with the reduced autophagy observed during AD. However, the lack of MT III also 
corresponded with decreased oxidant-induced zinc release, revealing the need for further studies 
to fully understand the role of MT III and its association with zinc in autophagic dysfunction. 
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Nonetheless, the fact that changes in MT III expression are almost universally observed in AD 
suggests that deregulation of MT III is likely contributing to the zinc dyshomeostasis observed. 
1.11 ZINC AND ITS RELATION TO CALCIUM DEREGULATION  
Like zinc, intracellular calcium dyshomeostasis also appears to play a crucial role in AD-related 
pathology (LaFerla, 2002; Berridge et al., 2010; Berridge 2013). Free intracellular calcium is 
normally in the nanomolar range within neurons; however, cellular injury can cause deregulation 
of the cation, resulting in a marked increase in the intracellular calcium concentration that can 
lead to cellular dysfunction. Further, simultaneous increases in intracellular zinc and calcium 
have been observed in a number of injurious signaling cascades related to ischemic, excitotoxic, 
and oxidative injury (Sensi et al., 2002; Medvedeva et al., 2009; Vander Jagt et al., 2009). 
However, details regarding the downstream signaling pathways activated by these two metals 
during oxidative injury are just beginning to be clarified (McCord and Aizenman, 2013). 
Similarly, although evidence has implicated calcium dyshomeostasis as a trigger for AD 
pathology (Khachaturian, 1989), if and how calcium and zinc cooperate to regulate pathological 
signaling during AD is still unclear. While there is some indication of a correlation between 
intracellular zinc and calcium levels in AD brains (Ishihara et al., 2002), direct evidence linking 
the two metals to pathological processes specifically associated with this disorder does not yet 
exist. Still, despite the lack of definitive proof, intracellular calcium and zinc release do appear to 
mediate many of the same processes during AD. 
Just as Aβ can induce zinc liberation from internal, metal-binding stores via ROS 
production, the peptide can also trigger calcium release from the ER. This increase in calcium 
 21 
leads to ROS generation, mitochondrial dysfunction, caspase activation, and apoptosis (Ferreiro 
et al., 2006). As discussed earlier, all of these cellular changes have also been reported during 
oxidant-induced, zinc- and calcium-mediated neuronal apoptosis. Additionally, like zinc, cellular 
alterations induced by increased intracellular calcium contribute to intraneuronal Aβ 
accumulation and neurotoxicity (Pierrot et al., 2006; Demuro et al., 2013). Specifically, a 
depolarization-induced increase in cytosolic calcium can trigger phosphorylation of APP and tau, 
leading to subsequent Aβi accumulation and cell death (Pierrot et al., 2006). These calcium-
dependent phosphorylation events were mediated by GSK-3β, a kinase known for its role in the 
phosphorylation of both tau and APP (Aplin et al., 1996) that has previously been shown to be 
activated downstream of ER calcium release (Hartigan and Johnson, 1999). Zinc can also induce 
GSK-3β phosphorylation, an event that corresponds to zinc-mediated activation of p38 MAPK 
(An et al., 2005). In another study, accumulation of Aβi was shown to trigger IP3-mediated 
calcium release from the ER that was necessary for Aβi-induced toxicity (Demuro et al., 2013). 
Like zinc, changes in intracellular calcium levels are extremely sensitive to oxidative 
stress. DTDP, a common inducer of intracellular zinc release (Aizenman et al., 2000; 
McLaughlin et al., 2001), has also been shown to trigger calcium release from the sarcoplasmic 
reticulum following oxidation of ryanodine receptors (RyRs) in cardiomyocytes (Zaidi et al., 
1989). Further, DTDP-induced ER calcium release has recently been observed during zinc-
dependent apoptosis in cortical neurons (McCord and Aizenman, 2013). Additionally, RyRs can 
also be nitrosylated by nitric oxide, leading to calcium release (Xu et al., 1998; Kakizawa et al., 
2013). Deregulation of both the ER and mitochondria and the resultant effects on intraneuronal 
calcium levels appear to be important determinants of the progression of AD-related pathological 
processes (Green et al., 2008; Mattson, 2010; Adam-Vizi et al., 2010). Both oxidative stress and 
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mitochondrial dysfunction have been shown to occur early in the pathogenesis of AD 
(Nunomura et al., 2001; Moreira et al., 2006), and mitochondria and the ER can physically 
interact to regulate intracellular calcium levels in response to changes in redox state (Csordas and 
Hajnoczky, 2009; Hayashi et al., 2009). As mentioned previously, intracellular zinc can also 
regulate mitochondria and ROS production (Dineley et al., 2003; Sensi et al., 2003). Further, 
increased intracellular calcium triggered by glutamate exposure has been shown to contribute to 
mitochondrial ROS production and subsequent release of zinc from intracellular stores (Dineley 
et al., 2008). While these studies were not specific to any one disease, it is conceivable that 
similar injurious parallel processes are taking place during AD and other neurodegenerative 
disorders. In fact, a signaling cascade has been proposed to account for the seemingly 
coordinated pathways activated by zinc and calcium during AD (Corona et al., 2011). Taken 
together, and considering the interrelated roles of calcium and zinc in other injury models, work 
to reveal potential parallel processing by the metals awaits as an exciting new opportunity to 
enhance our understanding of the cellular signaling events underlying AD neuropathology. 
1.12 ROLE OF KV2.1 CHANNELS IN HEALTH AND DISEASE 
1.12.1 Physiological functions of Kv2.1 
As mentioned previously, a necessary downstream event in oxidant-induced, zinc-mediated 
apoptosis is increased K+ efflux through the delayed-rectifier Kv2.1 channel. Kv2.1 is one 
member of the voltage-gated potassium (Kv) channel family, a class of ion channels comprised 
of 12 subtypes (Kv1-12) that are critical in the regulation of neuronal excitability (Pongs, 1999; 
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Gutman et al., 2005; Johnston et al., 2010). Kv channels consist of four α subunits, each 
composed of six transmembrane domains, as well as a cytoplasmic N- and C-terminus. Kv2.1, 
one of two members of the delayed rectifying Kv2 α subunit-containing family, is characterized 
by its slow gating kinetics, activation at relatively depolarized potentials (Frech, et al., 1989; Du 
et al., 2000), and localization to the soma, proximal dendrites, and axon initial segments of 
neurons (Trimmer, 1991; Scannevin et al., 1996; Sarmiere et al., 2008).  
           While Kv2.1 does play a role in controlling membrane potential, studies over the past 15 
years have found that the channel has unique properties in this regard that are not typical of most 
Kv channels. Kv2.1 is responsible for conducting the majority of current encompassing the 
delayed rectifier K+ current, IK (Murakoshi and Trimmer, 1999). However, unlike many other Kv 
channels, which can influence membrane potential even after a single action potential, Kv2.1 
does not normally regulate neuronal function as related to single action potentials, nor does it 
normally affect passive electrical properties of neurons such as resting membrane potential and 
input resistance (Du et al., 2000; Guan et al., 2013). Instead, Kv2.1 channel-mediated currents 
only become significant in conditions that induce repetitive action potential firing (Du et al., 
2000; Mohapatra et al., 2009), and thus serve to diminish the neuronal responses to periods of 
heightened activity. As such, Kv2.1 is regarded as a regulator of homeostatic plasticity, a term 
applied to a neuron’s ability to maintain an optimal level of intrinsic activity despite continuous 
fluctuations in synaptic input (Surmeier and Foehring, 2004). 
1.12.2 Kv2.1 phosphorylation regulates channel activity 
One of the primary determinants of Kv2.1 function is the phosphorylation status of the channel. 
Kv2.1 is highly phosphorylated under normal conditions (Park et al., 2006), and the large 
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number of phosphates near the channel’s voltage sensor is thought to influence the voltage-
dependence of activation such that Kv2.1 only becomes activated at relatively depolarized 
potentials (Perozo and Bezanilla, 1990; Du et al., 2000). Calcineurin-dependent 
dephosphorylation of several C-terminal residues results in a leftward shift in the voltage-
dependence of channel activation as a means to regulate neuronal excitability during periods of 
high-frequency firing (Murakoshi et al., 1997; Du et al., 2000). Interestingly, exposure to 
injurious excitatory stimuli such as glutamate or kainic acid also leads to Kv2.1 
dephosphorylation and subsequent hyperpolarization of the channel’s activation voltage, again in 
order to prevent neural overexcitation (Misonou et al., 2004; Park et al., 2006). Moreover, 
calcineurin-mediated dephosphorylation of Kv2.1 also affects channel localization. As 
mentioned, a large proportion of Kv2.1 channels are normally maintained in dense clusters at 
neuronal plasma membranes (Trimmer, 1991). Activity-dependent dephosphorylation of these 
channels triggers their dispersal into a more uniform localization, although at present, the 
purpose of channel declustering is unclear. Interestingly, Kv2.1 phosphorylation state, voltage-
dependence of activation, and channel localization all appear to be mediated by an association 
between the channel’s N and C termini, as disruption of this interaction influences each of these 
parameters (Mohapatra et al., 2008). 
Calcineurin-independent phosphorylation of two distinct Kv2.1 channel residues, N-
terminal Y124 and C-terminal S800, by zinc-mediated activation of Src kinase and p38 MAPK, 
can also influence channel activity, although phosphorylation of these sites is thought to occur 
solely during apoptosis, and functions to enhance K+ efflux upstream of cell death (Redman et 
al., 227, 2009).  In this case, whether the N and C termini physically interact has yet to be 
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documented, although it does appear that the phosphorylation status of residues Y124 and S800 
may be interdependent (Figure 6B; Redman et al., 2009; unpublished observations).  
1.12.3 Kv2.1 as a facilitator of exocytosis 
In addition to their role as regulators of neuronal excitability, Kv2.1 channels have also been 
shown to be an important constituent of the cellular machinery responsible for large dense core 
vesicle (LDCV)-mediated exocytosis. The role of Kv2.1 during exocytosis appears to be 
dynamic and context-dependent, as the channel has been shown to function in two independent 
capacities in this regard. First, Kv2.1 can suppress depolarization-induced release via its more 
traditional role in the hyperpolarization of the membrane potential (MacDonald et al., 2002; 
MacDonald and Wheeler, 2003). Conversely, Kv2.1 has also been shown to facilitate exocytosis 
via an interaction with syntaxin. However, these studies, carried out in the same laboratory, 
revealed a discrepancy in the mechanism underlying Kv2.1 modulation by syntaxin, suggesting 
dynamic regulation of the channel. Namely, an initial report found that the binding of syntaxin to 
Kv2.1 promoted exocytosis by inhibiting surface delivery of the channel, which reduced K+ 
efflux, thereby minimizing hyperpolarization of the membrane potential (Leung et al., 2003). 
Later studies, however, found that Kv2.1/syntaxin binding regulates exocytosis entirely 
independently of the channel’s ability to conduct K+ (Singer-Lahat et al., 2007; Feinshreiber et 
al., 2010; Dai et al., 2012). Specifically, Kv2.1/syntaxin binding facilitated secretion by 
enhancing vesicle recruitment to the plasma membrane, and this effect was observed even with a 
non-conducting Kv2.1 channel mutant (Feinshreiber et al., 2010). Thus, depending on the 
environment, Kv2.1 can either inhibit or enhance vesicle release, the latter scenario occurring 
through either a channel pore-dependent or pore-independent mechanism, both of which require 
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a physical interaction with syntaxin. Presumably, these disparities can be attributed to both the 
known activity dependence of vesicle release, and to the dynamic and context-dependent 
functioning of Kv2.1. Taken together, these findings suggest that the modulation of 
physiological Kv2.1 activity is a highly nuanced process, the details of which are still under 
investigation. 
1.12.4 Kv2.1-mediated K+ efflux and neuronal injury 
While Kv2.1 does regulate various physiological processes in neurons, the channel is also 
involved in a number of neuropathological processes, including those observed in AD. Low 
intracellular K+ is a requisite step in many apoptosis pathways, as it facilitates protease and 
nuclease activation, cytochrome c release from mitochondria, and apoptosis-related cellular 
volume decrease (Hughes et al., 1997; Yu et al., 1997; Bortner et al., 1997; Maeno et al., 2000; 
Cain et al., 2001). Intracellular zinc release and downstream Kv2.1-mediated K+ efflux can both 
be triggered by exposure to DTDP, NO, and activated microglia (Pal et al., 2003; Bossy-Wetzel 
et al., 2004; Knoch et al., 2008). Further, oxidant-induced K+ current enhancement is prevented 
by the zinc chelator TPEN, demonstrating the dependence of apoptotic Kv2.1 activity on zinc 
(McLaughlin et al., 2001).  
In addition to its role in zinc-mediated apoptosis, altered Kv2.1 activity has also been 
shown to be involved in the toxic cellular processes related to AD. For a number of years, studies 
have demonstrated an enhancement of voltage-gated, delayed rectifier K+ currents following 
exposure of neurons and astrocytes to Aβ (Jalonen et al., 1997; Yu et al., 1998; Colom et al., 
1998). More recently, though, changes specifically within the Kv2.1 channel have been 
identified in animal models of AD. Namely, upregulation of Kv2.1 mRNA and protein has been 
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reported in rats injected with Aβ; this change in Kv2.1 expression was accompanied by impaired 
performance on spatial memory tasks (Pan et al., 2004). It is well known that deficits in 
acetylcholine are intimately related to AD-associated cognitive decline, thus forming the basis of 
acetylcholinesterase (AChE)-based therapy in the disease (Bartus et al., 1982; Francis et al., 
1999). Interestingly, the acetylcholinesterase inhibitor galantamine, used in the treatment of AD, 
has been shown to cause a reduction in basal delayed rectifier K+ currents in hippocampal 
neurons (Pan et al., 2003; Vicente et al., 2010), likely arising from Kv2.1 channels (Zhang et al., 
2004b). 
Hydrogen peroxide exposure has been shown to directly oxidize Kv2.1 channels, leading 
to channel oligomerization and downstream apoptosis. Importantly, an oxidation-resistant Kv2.1 
channel cysteine mutant (C73A) that prevented oligomerization also attenuated toxicity induced 
by Aβ exposure (Cotella et al., 2012). Interestingly, enhanced oligomerization of Kv2.1 was also 
observed in a mouse model of AD, although how this change in Kv2.1 structure contributed to 
AD-related cognition decline was not determined (Cotella et al., 2012). In contrast to reports of 
enhanced Kv2.1-mediated K+ currents during apoptosis, this study found that oxidant exposure 
actually decreased K+ currents, and the Kv2.1C73A mutation blocked this effect. However, this 
discrepancy could be explained by the fact that it takes ~3 hours to observe the Kv2.1-mediated 
K+ current enhancement after oxidant exposure (McLaughlin et al., 2001), and this group only 
examined currents immediately following the oxidative insult. Further, the toxic effects of Kv2.1 
channel oligomerization may have occurred independently of the change in K+ currents, as a 
second oligomerization-impaired channel mutant (C73S) was found to be non-conducting, yet 
still rescued cells from oxidant-induced apoptosis (Cotella et al., 2012). Thus, it is not yet clear 
how alterations in Kv2.1-mediated K+ currents may influence Aβ-mediated toxicity. 
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1.13 CONCLUSIONS 
Oxidative stress can generally be considered both a cause and an effect of the neuropathological 
changes seen in AD and other age-related neurodegenerative disorders. In addition, links 
between increased intracellular zinc, oxidative stress, and age-related neurodegeneration have 
been established in numerous studies, and zinc dyshomeostasis appears to be a common 
constituent of a multitude of pathological neuronal processes. Nonetheless, a direct causative role 
of intracellular zinc release in human neurodegenerative disorders has yet to be firmly 
established. It is known that zinc homeostasis is critical for proper brain function, and even 
minor disturbances to this delicate balance can trigger an accumulation of zinc, which can have 
extremely adverse effects on the fate of neurons in AD and related disorders. As such, 
modulation of intracellular zinc levels could be a particularly important target in order to protect 
against AD-related injurious cellular pathways. However, while chelation of zinc may be an 
effective neuroprotective strategy in vitro, the potential therapeutic benefits of zinc chelation 
become much more complex when studying changes in zinc levels in vivo, in particular as zinc 
can also act as a neuromodulator or neurotransmitter, and it has a wide range of additional 
essential functions in neurons, as well as throughout the organism, including, but not limited to 
regulation of gene expression. This matter is thus complicated by the fact that both increased and 
decreased intracellular zinc can be neurotoxic, presumably depending on specific cellular 
conditions. Still, the fact that drugs like the zinc ionophore clioquinol have been effective in 
abrogating some of the pathological consequences of AD in clinical trials (Regland et al., 2001; 
Ritchie et al., 2003), presumably through its effect on modulating zinc levels, indicates that the 
metal plays a pivotal role in the progression of AD, and that strategies targeting zinc could hold 
the key to finding better treatments for this currently incurable disease. Still, future work is 
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required to determine exactly how clioquinol and its association with zinc improve the outcome 
of AD progression. Further, investigation into the potential off-target effects of this drug is 
crucial, as increased intracellular zinc, as illustrated throughout this review, is lethal to neurons 
in a variety of settings. 
1.14 THESIS GOALS 
The goal of my dissertation was to elucidate upstream signaling cascades responsible for the 
introduction of Kv2.1 K+ channels into the plasma membrane and consequent loss of 
intracellular K+ that has come to be regarded as a requisite event in neuronal apoptosis. Both 
intracellular zinc release and enhanced K+ efflux are common constituents of numerous 
apoptosis pathways, and our laboratory has worked to uncover several the intermediate cellular 
signals linking these two injurious processes. Although calcium dysregulation has also been 
implicated in neuronal apoptosis, whether signals activated by this metal converge on cellular K+ 
efflux had not been described.  My research project was directed at uncovering potential 
cooperative convergence of calcium and zinc in Kv2.1-dependent neuronal apoptosis. I first 
determined whether calcium-dependent activation of CaMKII facilitated the apoptotic K+ current 
enhancement and downstream apoptosis, and the molecular signaling process activated by this 
kinase. These findings are detailed in Chapter 2, and have formed the basis of a manuscript that 
was recently published (McCord and Aizenman, 2013). The studies presented in Chapter 2 also 
uncovered a role for the SNARE protein syntaxin in the modulation of Kv2.1 activity during 
apoptosis. Thus, in subsequent experiments I examined in more detail how syntaxin regulated 
Kv2.1, and how interfering with this interaction affected viability of oxidatively stressed 
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neurons. The results are presented in Chapter 3, and are currently being compiled into a 
manuscript for publication. The findings comprising my thesis establish how calcium initiates an 
injurious signaling cascade that works cooperatively with a known zinc-initiated cascade to 
mediate the apoptotic membrane insertion of Kv2.1 channels. As such, this dissertation serves to 
integrate a previously unrecognized cellular signaling cascade into an established zinc- and 
Kv2.1-dependent apoptosis pathway. 
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2.0  CONVERGENT CALCIUM AND ZINC SIGNALING REGULATES 
APOPTOTIC KV2.1 POTASSIUM CURRENTS 
2.1 ABSTRACT 
A simultaneous increase in cytosolic zinc and calcium accompanies the initiation of neuronal cell 
death signaling cascades. However, the molecular convergence points of cellular processes 
activated by these cations are poorly understood. Here, we show that calcium-mediated 
activation of the calcium/calmodulin-dependent protein kinase II (CaMKII) is required for a cell 
death-enabling process previously shown to also depend on zinc. We have reported that oxidant-
induced intraneuronal zinc liberation triggers a syntaxin-dependent incorporation of Kv2.1 
channels into the plasma membrane. This can be detected as a marked enhancement of delayed 
rectifier K+ currents in voltage clamp measurements observed at least three hours following a 
short exposure to an apoptogenic stimulus. This is the process responsible for the cytoplasmic 
loss of K+ that enables protease and nuclease activation during apoptosis. In the present study, 
we demonstrate that an oxidative stimulus also promotes intracellular calcium release and 
downstream activation of CaMKII, which, in turn, modulates the ability of syntaxin to interact 
with Kv2.1. Pharmacological or molecular inhibition of CaMKII prevents the K+ current 
enhancement observed following oxidative injury and, importantly, significantly increases 
neuronal viability. These findings reveal a previously unrecognized cooperative convergence of 
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calcium- and zinc-mediated injurious signaling pathways, providing a potential new target for 
therapeutic intervention in neurodegenerative conditions associated with oxidative stress. 
2.2 INTRODUCTION 
Calcium has long been recognized as a critical component of neuronal cell death pathways 
triggered by oxidative, ischemic, and other forms of injury (Choi, 1995). Indeed, calcium 
deregulation has been associated with a variety of detrimental processes in neurons, including 
mitochondrial dysfunction (Sims and Anderson, 2002), generation of reactive oxygen species 
(Gleichmann and Mattson, 2011), and activation of apoptotic signaling cascades (Elmore, 2007). 
More recently, zinc, a metal crucial for proper cellular functioning (Maret, 2013), has been found 
to be closely linked to many of the injurious conditions in which calcium had been thought to 
play a prominent role (Calderone et al., 2004; Bonanni et al., 2006; Lee and Koh, 2010; 
Shuttleworth and Weiss, 2011; Sensi et al., 2011). In fact, it has been suggested that a number of 
deleterious properties initially attributed to calcium may have significant zinc-mediated 
components (Stork and Li, 2006; Vander Jagt et al., 2009). Although it is virtually impossible to 
chelate, or remove calcium without disrupting zinc levels (Smith, 2009), the introduction of 
techniques to monitor calcium and zinc simultaneously in cells (Devinney et al., 2005) has made 
it increasingly apparent that both cations have important yet possibly distinct roles in neuronal 
cell death (Vander Jagt et al., 2009; Sensi et al., 2002; Dietz et al., 2009; Medvedeva et al., 2009; 
Martin et al., 2011). However, the relationship between the cell death signaling pathways 
activated by the cations is unclear, and possible molecular points of convergence between these 
signaling cascades have yet to be identified. 
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Injurious oxidative and nitrosative stimuli lead to the liberation of intracellular zinc from 
metal binding proteins (Aizenman et al., 2000). The released zinc, in turn, triggers p38 MAPK- 
and Src-dependent Kv2.1 channel insertion into the plasma membrane, resulting in a prominent 
increase in delayed rectifier K+ currents in dying neurons, with no change in activation voltage, 
approximately 3 hours following a brief exposure to the stimulus (Yu et al., 1997; McLaughlin et 
al., 2001; Pal et al., 2003; Pal et al., 2006; Redman et al., 2007; Redman et al., 2009; Shepherd et 
al., 2012). The increase in Kv2.1 channels present in the membrane mediates a pronounced loss 
of intracellular K+, likely accompanied by chloride (Wei et al., 2004; Bortner and Cidlowski, 
2007), that facilitates apoptosome assembly and caspase activation (Yu et al., 1997; Bortner et 
al., 1997; Hughes et al., 1997; Montague et al., 1999; Hughes and Cidlowski, 1999; Cain et al., 
2001; Thompson et al., 2001). Indeed, K+ efflux appears to be a requisite event for the 
completion of many apoptotic programs, including oxidant-induced, zinc-mediated neuronal 
death (McLaughlin et al., 2001). 
Calcium has been suggested to regulate the p38 MAPK signaling cascade via CaMKII-
mediated activation of the MAP3K apoptosis signaling kinase-1 (ASK-1; Takeda et al., 2004). 
As ASK-1 is also required for p38-dependent manifestation of the zinc-triggered, Kv2.1-
mediated enhancement of K+ currents (Aras and Aizenman, 2005), we hypothesized that the p38 
activation cascade may provide a point of downstream convergence between calcium and zinc 
signals following oxidative injury. Here, we report that calcium and zinc signals do in fact 
converge on a cellular event critical for the K+ current enhancement, and that CaMKII is required 
for this process. However, CaMKII does not act upstream of p38 activation as originally 
hypothesized, but instead interacts with the N-ethylmaleimide-sensitive factor attachment protein 
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receptor (SNARE) protein syntaxin, which we previously showed to be necessary for the 
insertion of Kv2.1-encoded K+ channels following an apoptotic stimulus (Pal et al., 2006). 
2.3 MATERIALS AND METHODS 
Cell Culture and Transfection Procedures. For electrophysiological experiments, mixed 
cortical neuronal/glial cultures were prepared from embryonic day 16 (E16) Sprague–Dawley 
rats (Charles River Laboratories, Wilmington, MA, USA). Cortices were dissociated with 
trypsin, and the resultant cell suspension, adjusted to 670,000 cells per well, was plated on glass 
coverslips in 6-well plates as described previously (Hartnett et al., 1997). Non-neuronal cell 
proliferation was inhibited after two weeks in culture with 1–2 µM cytosine arabinoside, and 
cultures utilized at three to four weeks in vitro. For biochemical experiments, neuronal-enriched 
cultures (Rosenberg and Aizenman, 1989) were prepared from E18 rats and seeded onto culture 
plates at a density of 470,000 cells per well. Cytosine arabinoside was applied five days after 
plating to reduce the glial cell population, and cultures were used at 12–14 days in vitro. For 
neuronal transfection, cells were treated for five hours in serum free medium with 2 µL 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 50 µL Optimem (GIBCO, Grand Island, NY), 
and 1.5 µg DNA per well. For Chinese hamster ovary (CHO) cell transfections, cells were plated 
on coverslips in 24-well plates at a density of 5.6 x 104 cells per well for electrophysiological 
measurements or in 100 mm dishes at a density of 1.7 x 106 cells per dish for biochemical 
studies. Cells were treated for 3-4 hours in serum free medium with a total of 1.2 µL 
Lipofectamine and 0.28 µg DNA per well for electrophysiology, or 55.1 µL Lipofectamine and 
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7.334 µg DNA per dish for biochemistry. Following transfection, cells were maintained in F12 
medium containing fetal bovine serum at 37°C, 5% CO2 for 24 hours prior to experimentation. 
Drug Treatments and Antibodies. The apoptotic stimulus for electrophysiological and 
biochemical experiments was 10 minute exposure to 30 µM 2,2’-dithiodipyridine (DTDP) at 
37°C, 5% CO2. For electrophysiology, the DTDP-containing solution was removed prior to 
three-hour incubation in fresh medium containing 10 µM butoxy-carbonyl-aspartate-
fluoromethyl ketone (BAF), a cysteine protease inhibitor that maintains cell viability without 
affecting K+ currents. Myristoylated CaMKIINtide (1 µM; EMD, Gibbstown, NJ) was used to 
inhibit CaMKII; thapsigargin (1 µM; Sigma Aldrich, St. Louis, MO) was used to deplete 
endoplasmic reticulum calcium stores. N,N,N’,N’-tetrakis-(2-pyridylmethyl)ethylenediamine 
(TPEN, 3 µM) and BAPTA-AM (100 µM) were used to chelate zinc and calcium, respectively. 
Antibodies were purchased from the following suppliers: rabbit anti-p38, anti-phospho-p38, anti-
CaMKIIα, and anti-phospho-CaMKII from Cell Signaling Technologies (Danvers, MA); rabbit 
anti-syntaxin from Abcam (Cambridge, MA); rabbit anti-oxidized-CaMKII were either a gift 
from M. Anderson (University of Iowa Carver College of Medicine) or purchased from Millipore 
(Temecula, CA); mouse anti-Kv2.1 from NeuroMab (Davis, CA); mouse anti-phospho-tyrosine 
from BD Biosciences (San Jose, CA); mouse anti-CaMKII from Santa Cruz Biotechnology 
(Dallas, TX). Immunoaffinity-purified serum directed at phosphorylated S800 of Kv2.1 was 
prepared in our laboratory (Redman et al., 2007); rabbit anti-phospho-Kv2.1S603 antibodies 
were a gift from J. Trimmer (University of California Davis). 
Electrophysiological Measurements. Current recordings were performed on eGFP-
positive co-transfected neurons or CHO cells using the whole-cell patch clamp configuration 
technique as described previously (McLaughlin et al., 2001). The intracellular (electrode) 
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solution contained (in mM): 100 K-gluconate, 11 EGTA, 10 KCl, 1 MgCl2, 1 CaCl2 x 2H2O, 10 
HEPES; pH adjusted to 7.2 with concentrated KOH; 2.2 ATP and 0.33 GTP were added and the 
osmolarity was adjusted to 280 mOsm with sucrose. The extracellular solution contained (in 
mM): 115 NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 D-glucose; 0.25 µM tetrodotoxin; pH 
adjusted to 7.2. Measurements were obtained under whole-cell voltage clamp with an Axopatch-
1D amplifier and pClamp software (Molecular Devices, Sunnyvale, CA), using 2-3 MΩ 
recording electrodes. Electrodes were pulled from 1.5 mm borosilicate glass (Warner 
Instruments, Hamden, CT) with a model P-97 mechanical pipette puller (Sutter Instruments, 
Novato, CA). Series resistance was partially compensated (80%) in all cases. Currents were 
filtered at 2 kHz and digitized at 10 kHz with a Digidata 1440A Digitizer (Molecular Devices). 
K+ currents were evoked with incremental 10 mV voltage steps to +80 mV from a holding 
potential of –80 mV. To determine current density values, steady-state current amplitudes were 
measured 180 msec after the initiation of the +10 mV step and normalized to cell capacitance. 
Viability Assays. Viability in transfected neurons was assessed using a luciferase 
reporter assay (Boeckman and Aizenman, 1996; Aras et al., 2008). Twenty-four hours after 
transfection with a luciferase reporter plasmid and any other plasmids of interest, cultures were 
treated overnight with either vehicle or microglia (50,000 cells/mL) (Cheepsunthorn et al., 2001) 
plated directly on top of neurons and activated by interferon-γ (IFN-γ) and lipopolysaccharide 
(LPS) (Knoch et al., 2008). Cells were then assayed for luciferase-mediated luminescence using 
a SteadyLite luciferase assay system (PerkinElmer, Waltham, MA). The luciferase reagent was 
added directly to cells and luminescence measured after 10 minutes using a Wallac 1420 96-well 
microplate reader (PerkinElmer Life Sciences, Waltham, MA). Cell viability is proportional to 
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luciferase luminescence, confirmed by cell counts in GFP co-transfected sister coverslips (Aras 
et al., 2008). 
Electrophoresis and Immunoblotting. Protein samples from equal amounts of cell 
lysate were separated on 7.5% or 10% sodium dodecyl sulphate (SDS) polyacrylamide gels by 
electrophoresis using the Mini Protean 3 System (Bio-Rad, Hercules, CA). Separated protein 
bands were transferred onto 0.2 µm nitrocellulose membranes (Bio-Rad), blocked with 1% 
Bovine Serum Albumin (BSA) in PBS with 0.05% Tween 20 (PBST) at room temperature for 1 
hour, and probed with appropriate primary antibodies diluted in PBST. Blots were then 
incubated with infrared fluorescent goat secondary antibodies at room temperature for 1 hour, 
visualized using the Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE), and 
quantified using infrared fluorimetry. 
Immunoprecipitation. Protein was harvested by washing cell culture dishes twice with 
ice cold PBS followed by a five-minute incubation with 1% 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS) buffer. Protein A/G agarose bead slurry (Santa 
Cruz, Dallas, TX) was added to the samples and rocked at 4°C for 1 hour in order to pre-clear 
non-specific protein binding. Samples were then incubated overnight at 4°C with the appropriate 
immunoprecipitating antibodies. The next day, following another incubation with the bead 
slurry, the protein samples were prepared/denatured by the addition of sample preparation buffer 
(625 mM Tris, 25% glycerol, 2% SDS, 0.01% bromophenol blue and 5% β -mercaptoethanol) 
and heated at 95°C for 5 min prior to SDS-PAGE gel electrophoresis and immunoblotting. 
Intraneuronal zinc and calcium Imaging. To assess changes in intracellular free zinc, 
the zinc-sensitive fluorescent reporter FluoZin-3 (Molecular Probes, Carlsbad, CA) was utilized. 
FluoZin-3 responds robustly to small changes in zinc, is insensitive to high calcium and 
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magnesium, and is unaffected by low intracellular pH or oxidants (Devinney et al., 2005). 
Further, zinc signals from surrounding astrocytes are minimal under these conditions, as these 
cells appear to buffer intracellular zinc more effectively than neurons (Dineley et al., 2000). 
Intracellular calcium levels were measured using the ratiometric, fluorescent calcium dye Fura-2 
(Teflabs, Austin, TX). Coverslips were loaded with either FluoZin-3 AM or Fura-2 AM (5 µM, 
30 minutes) and immediately transferred to a recording chamber (Warner, Hamden, CT) 
mounted on an inverted epifluorescence microscope. Using a computer controlled 
monochromator (Polychrome II, TILL photonics, Martinsried, Germany) and CCD camera 
(IMAGO, TILL photonics), images were acquired every 10 seconds by exciting cells with 485 
nm light (measured at 520 nm emission) for zinc imaging, or alternately with 340 and 380 nm 
light (measured at 510 nm emission) for calcium imaging. After background subtraction, 
fluorescence was expressed as the difference between the average baseline fluorescence just 
before treatment and the average peak fluorescence during treatment (ΔF) for 10-20 neurons per 
coverslip. 
Data analysis. Data are expressed as mean ± SEM. Statistical analysis was performed 
using Student’s t test or ANOVA with post hoc comparisons, as indicated in figure legends. An 
α of p<0.05 was considered statistically significant. 
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2.4 RESULTS 
2.4.1 Injurious oxidant exposure leads to CaMKII activation in neurons 
Exposure to the thiol oxidant 2,2’-dithiodipyridine (DTDP) liberates intracellular zinc and 
enables neuronal injury via a p38- and Kv2.1-dependent process (Aizenman et al., 2000; 
McLaughlin et al., 2001). However, DTDP has also been shown to induce intracellular calcium 
release in cardiomyocytes through cysteine oxidation of sarcoplasmic reticulum ryanodine 
receptors (Zaidi et al., 1989). Thus, the first step in uncovering a possible role for calcium in 
zinc-dependent oxidative injury was to determine if DTDP caused a similar increase in calcium 
in neurons. First, we confirmed the effects of DTDP on intraneuronal zinc release using the 
specific fluorescent zinc indicator FluoZin-3 AM (Gee et al., 2002). As expected (Aizenman et 
al., 2000), we observed a pronounced increase in fluorescent signal in cultured rat cortical 
neurons following 30 µM DTDP exposure, which was abolished by concurrent treatment with 
the zinc chelator N,N,N’,N’-tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN; 3 µM). TPEN 
was also sufficient to decrease basal FluoZin-3 fluorescence, presumably by effectively 
competing with the fluorescent indicator for the cation (Figure 1A). 
To monitor DTDP-induced changes in intraneuronal calcium, we used the fluorescent 
calcium indicator Fura-2 AM. Cortical neurons were exposed to 30 µM DTDP in the presence of 
3 µM TPEN to chelate any liberated zinc that would otherwise interfere with a measureable 
calcium signal, as Fura-2 also detects free zinc (Grynkiewicz et al., 1985). Exposure to DTDP + 
TPEN led to a significant increase in Fura-2 fluorescence, demonstrating that, similar to 
cardiomyocytes, the oxidizing agent also induces a calcium response in neurons. To identify the 
source of the released calcium, we depleted endoplasmic reticulum (ER) calcium stores with the 
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ER calcium-ATPase inhibitor thapsigargin (TG; 1 µM) prior to exposure to DTDP + TPEN. 
Under these conditions, exposure to the thiol-oxidizing agent did not generate a change in 
fluorescence, confirming that the released calcium originates from the ER (Figure 1B). Of note, 
ryanodine receptors, which as mentioned earlier can be gated by DTDP (Zaidi et al., 1989), 
spatially co-localize with Kv2.1 channel clusters in neurons (Antonucci et al., 2001). 
To determine if DTDP-induced calcium release led to activation of CaMKII, 
immunoblotting was performed on protein samples obtained from neuronal cultures treated with 
30 µM DTDP alone or in combination with either 3 µM TPEN or the acetoxymethyl ester of the 
calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis (BAPTA-
AM; 100 µM). DTDP exposure caused a significant increase in T286-phosphorylated (active) 
CaMKII, which was unaffected by zinc chelation but blocked by BAPTA-AM (Figure 1C). 
These results indicate that DTDP-liberated calcium, but not zinc, is responsible for CaMKII 
phosphorylation. In addition to calcium-dependent activation of CaMKII, sustained activation of 
the kinase can be achieved via the oxidation of its M281/282 residues (Erickson et al., 2008). 
However, we observed no difference in immunoblots obtained from CaMKII-
immunoprecipitated protein samples from vehicle- and DTDP-treated neurons using an antibody 
directed toward the oxidized forms of M281/282 (Figure 1D; 100 µM H2O2 serving as a positive 
control, Figure 2). Therefore, it is unlikely that oxidative CaMKII activation appreciably 
contributes to the signaling cascades triggered by coordinated intracellular release of calcium and 
zinc. Lastly, we found that activation of CaMKII, in and of itself, does not influence zinc release, 
as treatment with the myristoylated (myr) inhibitory CaMKII peptide CaMKIINtide (1 µM) prior 
to DTDP exposure had no effect on FluoZin-3 fluorescence (Figure 1A). Taken together, these 
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results demonstrate that a thiol oxidative insult, previously shown to initiate a zinc-mediated cell 
death pathway in neurons, can also trigger calcium-dependent activation of CaMKII. 
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Figure 1: Oxidant exposure leads to intracellular zinc and calcium release and CaMKII activation 
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Figure 1. (A) Neurons loaded with the zinc indicator FluoZin-3 AM were exposed to DTDP (30 
µM) with or without TPEN (3 µM). A subset of cells was exposed to myr-CaMKIINtide (1 µM) 
prior to DTDP treatment. Left: representative responses averaged from ~15 cells from a single 
coverslip. Arrow indicates start of drug application (calibration: 15 absolute units or a.u., 2 min; 
FluoZin-3 emission measured at 520 nm). Right: quantified results, with ΔF equal to the 
difference between the average baseline fluorescence just before DTDP treatment and the 
average maximal fluorescence during treatment (mean ± SEM, n=5-7; ***p<0.001, paired t-test). 
(B) Neurons loaded with the calcium indicator Fura-2 AM were exposed to DTDP (30 µM) in 
the presence of TPEN (3 µM); some coverslips were pre-treated with thapsigargin (TG; 1 µM, 
30 min) to deplete ER calcium. Left: representative responses averaged from ~15 cells in a single 
coverslip (calibration: 10 a.u., 2 min; Fura-2 emission measured at 510 nm). Right: quantified 
results (n=5; *p<0.05, paired t-test). (C) Representative immunoblot and quantified results from 
neuronal samples obtained under control conditions or after 10 min exposure to 30 µM DTDP in 
the absence or presence of either 3 µM TPEN or 100 µM BAPTA-AM. Blots were probed with 
antibodies specific for p-CaMKII or CaMKII. Data are expressed as a ratio of mean ± SEM 
signal of phospho to total CaMKII (n=5; **p<0.01, *p<0.05; ANOVA/Bonferroni). Neither 
TPEN nor BAPTA-AM alone significantly decreased CaMKII protein levels, when averaged 
across all experiments. (D) Representative immunoprecipitation and quantification of blots 
derived from neuronal samples obtained under control conditions or after 10 min exposure to 30 
µM DTDP with or without 3 µM TPEN. Following CaMKII immunoprecipitation, blots were 
probed with antibodies against oxidized M281/282 CaMKII or total CaMKII. Data are expressed 
as a ratio of mean ± SEM signal of oxidized to total CaMKII (n=3). 
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Figure 2: CaMKII methionine oxidation by hydrogen peroxide 
 
Figure 2. Representative immunoblot from protein samples were obtained from neuronal-
enriched cultures under control conditions or after 10-minute exposure to 100 µM H2O2. Blots 
were probed with antibodies specific for oxidized M281/282 CaMKII or total CaMKII. 
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2.4.2 CaMKII acts independently of p38 activation 
ASK-1, an upstream kinase in the p38 MAPK signaling pathway, has been reported to be 
activated by CaMKII in a calcium-dependent fashion (Takeda et al., 2004). Since zinc-triggered 
activation of p38 also requires ASK-1 (McLaughlin et al., 2001; Aras and Aizenman, 2005), we 
hypothesized that a convergence of calcium and zinc signaling processes may occur at the level 
of p38 phosphorylation. Immunoblots were obtained from protein samples of cortical neurons 
previously exposed to DTDP (30 µM) alone or in the presence of either myr-CaMKIINtide (1 
µM) or TPEN (3 µM). As expected (McLaughlin et al., 2001), TPEN significantly prevented the 
effect of DTDP on p38 phosphorylation. In contrast, myr-CaMKIINtide was unable to block this 
effect (Figure 3A). Thus, although DTDP-triggered calcium release leads to CaMKII activation 
in neurons, the kinase does not appear to be involved in the phosphorylation of p38 following 
zinc liberation.  
We next investigated if activity of the kinase was in fact required for an oxidant-induced 
increase in K+ currents. To explore this we utilized Chinese hamster ovary (CHO) cells, a 
recombinant expression system that lacks endogenous voltage-gated K+ channels (Pal et al., 
2003; Yu and Kerchner, 1998), yet has all the cell signaling components required to produce an 
apoptotic current surge in Kv2.1-transfected cells (Pal et al., 2003). CHO cells expressing Kv2.1 
with or without a kinase-inactive CaMKIIK42R mutant were subjected to a 10-minute exposure 
to 30 µM DTDP followed by 3-hour maintenance in butoxy-carbonyl-aspartate-fluoromethyl 
ketone (BAF; 10 µM), a broad-spectrum protease inhibitor used during recording for its ability to 
prevent apoptosis downstream of the K+ current enhancement (McLaughlin et al., 2001). We 
found that the DTDP-induced increase in K+ current densities seen in Kv2.1-expressing CHO 
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cells was absent in cells co-expressing CaMKIIK42R (Figure 3B), strongly suggesting that 
CaMKII activity is necessary for manifestation of the apoptotic K+ current enhancement. 
Kv2.1-expressing CHO cells were also used to confirm that the involvement of CaMKII 
in the K+ current enhancement occurs independently of p38 activation. Our group has shown that 
p38 directly phosphorylates Kv2.1 at residue S800, which is required for the apoptotic K+ current 
enhancement to commence (Redman et al., 2007). Moreover, CHO cells expressing a pseudo-
phosphorylated mutant, Kv2.1S800E, exhibit an innate, p38-independent increase in K+ current 
densities that mimics the enhanced currents observed in apoptogen-exposed, wild type Kv2.1-
expressing cells (Redman et al., 2007). Here, we observed that the increased current densities 
seen in Kv2.1S800E-expressing CHO cells were absent in cells that also expressed 
CaMKIIK42R (Figure 3C). These observations support our biochemical results obtained in 
neurons (Figure 3A) and strongly argue that although CaMKII is necessary for the increase in K+ 
currents, its site of action is distinct from the events leading to phosphorylation of Kv2.1 residue 
S800 by p38. 
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Figure 3: CaMKII modulates Kv2.1-mediated K+ currents independently of p38 activation 
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Figure 3. (A) Zinc chelation, but not CaMKII inhibition, prevents DTDP-induced p38 activation. 
Representative immunoblot and quantified results from neuronal samples obtained under control 
conditions or after 10 min exposure to 30 µM DTDP in the absence or presence of 1 µM 
CaMKIINtide or 3 µM TPEN. Blots were probed with antibodies specific for p-p38 or p38. Data 
are expressed as a ratio of mean ± SEM signal of phospho to total p38 (n=7 for control and n=6 
for CaMKIINtide and TPEN groups; *p<0.05; ANOVA/Bonferroni). Note that there was no 
significant effect of either treatment on basal p38 protein levels across all experiments. (B) 
Representative whole-cell K+ currents and pooled mean ± SEM current densities recorded from 
Kv2.1-expressing CHO cells treated (10 min) with either vehicle (n=15) or 30 µM DTDP 
(n=10), and CHO cells co-expressing Kv2.1 and CaMKIIK42R treated with vehicle (n=9) or 30 
µM DTDP (n=11). Recordings were performed 3 hr following exposure. (C) CaMKIIK42R 
blocks the K+ current enhancement induced by the Kv2.1S800E mutation. Representative whole-
cell K+ currents and corresponding mean ± SEM current densities recorded from CHO cells 
expressing either Kv2.1 (n=9), Kv2.1S800E (n=26), or Kv2.1S800E + CaMKIIK42R (n=10). 
Currents were evoked by a series voltage steps from -80 mV to +80 mV in 10 mV increments. 
To determine current density values, steady-state current amplitudes were measured 180 msec 
after the initiation of the +30 mV step and normalized to cell capacitance. Representative traces 
shown were selected as they match the current densities shown on the bar graphs. Calibration: 5 
nA, 25 msec; **p<0.01; ANOVA/Dunnett. 
 
 49 
2.4.3 CaMKII interacts with syntaxin 
CaMKII has previously been shown to regulate exocytosis via a specific interaction with 
syntaxin (Ohyama et al., 2002; Nomura et al., 2003; Hirling and Scheller, 1996; Bonanno et al., 
2005). In addition, syntaxin is known to bind to the most proximal region of the Kv2.1 C 
terminus, termed C1a, during calcium-facilitated exocytosis in pancreatic and other non-neuronal 
cells (Leung et al., 2003; Singer-Lahat et al., 2007, 2008). Importantly, we previously showed 
that syntaxin is also required for the membrane insertion of Kv2.1 channels during apoptosis (Pal 
et al., 2006). Based on these observations, and because CaMKII is also necessary for the K+ 
current increase, we hypothesized that an interaction between CaMKII and syntaxin would be 
detected in our system. Syntaxin immunoprecipitates of protein samples obtained from CHO 
cells transfected with a syntaxin-expressing plasmid, with or without Kv2.1, were probed for 
CaMKII. Results revealed that endogenous CaMKII co-immunoprecipitates with syntaxin, and 
that this interaction is enhanced by Kv2.1 co-expression (Figure 4A). In these experiments we 
also confirmed the previously described association of syntaxin and Kv2.1 (Figure 4A; Leung et 
al., 2003; Singer-Lahat et al., 2007, 2008). The increased CaMKII signal in Kv2.1-expressing 
cells could be the result of a direct interaction of the kinase with the K+ channel. Although we 
detected a measurable, albeit weak Kv2.1 signal in immunoblots obtained from CaMKII-
immunoprecipitated protein samples, this interaction was disrupted in cells overexpressing the 
C1a region of Kv2.1 (Figure 4B). As mentioned previously, C1a contains the channel’s syntaxin-
binding site, and can displace native Kv2.1 from syntaxin (Singer-Lahat et al., 2007). Thus, we 
suggest that syntaxin provides the link between CaMKII and Kv2.1. Nonetheless, we tested 
whether CaMKII overexpression in CHO cells could lead to phosphorylation of Kv2.1, as a low-
stringency scan of possible phosphorylation sites of the channel sequence (Obenauer et al., 2003) 
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revealed up to 7 putative serine targets for CaMKII. In contrast to a pronounced shift in the 
molecular weight of the channel following phosphorylation by cyclin-dependent kinase 5 
(CDK5), a known multiple-residue kinase of Kv2.1 (Cerda and Trimmer, 2011), CaMKII had no 
effect (Figure 5). Furthermore, the specific actions of CDK5 on Kv2.1 residue S603 
phosphorylation were confirmed with the use of a phospho-specific antibody (Cerda and 
Trimmer, 2011), again with CaMKII generating no signal (Figure 5). This result is altogether not 
surprising, however, given that calcium-dependent changes in Kv2.1 phosphorylation status have 
been primarily linked to calcineurin phosphatase activity and dephosphorylation of the channel 
(Mohapatra et al., 2007). 
Next, we tested whether phosphorylation of the Kv2.1 residues involved in the apoptotic 
K+ current enhancement led to an increased association of the channel and syntaxin. We also 
investigated whether interfering with CaMKII function disrupted this interaction. In addition to 
p38-dependent phosphorylation of Kv2.1 S800, an N-terminal Src kinase-targeted tyrosine 
(Y124; Tiran et al., 2003) is critical for the expression of the apoptotic current enhancement 
(Redman et al., 2009). We have recently found that overexpression of Src in CHO cells is 
sufficient to trigger maximal phosphorylation of both Y124 and S800, the latter likely occurring 
via activation of endogenous p38 (Figure 6; Mohapatra et al., 2007). Here, we found that Src 
overexpression in CHO cells significantly enhanced the ability of syntaxin to bind Kv2.1, and 
inclusion of the kinase inactive CaMKIIK42R mutant completely abolished this effect (Figure 
4C). These results indicate that changes in the phosphorylation profile of Kv2.1 that normally 
lead to the apoptotic K+ current enhancement are accompanied by an increased interaction of the 
channel with syntaxin, and that a functional CaMKII is necessary for this process. 
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Figure 4: CaMKII regulates Kv2.1/syntaxin binding 
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Figure 4. (A) Co-immunoprecipitation of CaMKII and syntaxin is enhanced in the presence of 
Kv2.1. Representative co-immunoprecipitation and quantification of blots derived from CHO 
cells transiently expressing syntaxin with or without Kv2.1. Following syntaxin 
immunoprecipitation, blots were probed with antibodies against Kv2.1, CaMKII, or syntaxin 
(mean ± SEM, n=4; *p<0.05; paired t-test). (B) Co-immunoprecipitation of Kv2.1 and CaMKII 
is disrupted by overexpression of Kv2.1 C1a region, which contains the syntaxin binding site. 
Representative co-immunoprecipitation and quantified results from CHO cells transfected with 
Kv2.1 or Kv2.1 + C1a. Following CaMKII immunoprecipitation, blots were probed with 
antibodies against Kv2.1 or CaMKII (n=4; *p<0.05; paired t-test). (C) CaMKII inhibition 
prevents the increase in Src-mediated Kv2.1/syntaxin binding. Representative co-
immunoprecipitation and quantified results of protein samples from syntaxin-expressing CHO 
cells co-transfected with either Kv2.1, Kv2.1 + Src, Kv2.1 + CaMKIIK42R, or Kv2.1 + 
CaMKIIK42R + Src. Syntaxin was immunoprecipitated and blots were probed with antibodies 
against Kv2.1 or syntaxin (n=5; *p<0.05; paired t-test). 
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Figure 5: CaMKII does not cause phosphorylation-induced shift in molecular weight of Kv2.1 
 
Figure 5. Immunoblot from Kv2.1-expressing CHO cells co-transfected with CaMKII or CDK5 
+ p35 demonstrates that unlike CDK5, CaMKII does not elicit a phosphorylation-induced 
molecular weight shift of Kv2.1. Membranes were probed with antibodies specific for Kv2.1 or 
p-Kv2.1S603, a known target of CDK5 used to confirm the effect of the kinase on Kv2.1 (Cerda 
and Trimmer, 2011). 
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Figure 6: Src expression induces the phosphorylation of Kv2.1 by Src and endogenous p38 
 
Figure 6. (A) Cells were co-transfected with Kv2.1 and either Src or p38, and Kv2.1 was 
immunoprecipitated. Membranes were probed with antibodies specific for p-Kv2.1S800, p-
tyrosine, or Kv2.1 to serve as a loading control. (B) Cells were co-transfected with Kv2.1 and 
either Src, p38, or both. Immunoprecipitation of Kv2.1 was followed by probing with antibodies 
specific for p-S800 or p-tyrosine. 
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2.4.4 CaMKII is required for oxidant-induced K+ current enhancement and cell death in 
neurons 
Lastly, we evaluated whether disruption of CaMKII activity could prevent the endogenous 
apoptotic K+ current increase and be neuroprotective in oxidant-exposed cortical neurons. We 
observed that both myr-CaMKIINtide (1 µM) and transfection with CaMKIIK42R blocked the 
increased K+ current densities normally seen in neurons 3 hours after DTDP exposure (30 µM, 
10 min; Figure 7A, B). In a separate set of studies, we confirmed that the zinc chelator TPEN (3 
µM) also effectively inhibited the increase in K+ currents induced by DTDP exposure (Figure 8). 
Next, to determine if inhibition of CaMKII was neuroprotective, we transfected neurons with a 
plasmid encoding CaMKIIK42R (or empty vector) in addition to a luciferase-expressing plasmid 
used to assess viability in transfected cells (Aras et al., 2008). Neurons were later exposed to 
activated rat microglia (Cheepsunthorn et al., 2001), which we previously showed to be a 
powerful inducer of zinc-dependent, Kv2.1-mediated injury via peroxynitrite production (Knoch 
et al., 2008). We observed that neurons expressing CaMKIIK42R were significantly protected 
from microglia toxicity when compared to vector-expressing cells (Figure 7C). Moreover, 
neurons expressing this mutant were also protected from DTDP toxicity (60 µM, 10 min; Figure 
9). From these data we conclude that a CaMKII activity is necessary for both the K+ current 
enhancement and subsequent lethal injury in neurons. 
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Figure 7: CaMKII inhibition blocks apoptotic K+ current increase and cell death in neurons 
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Figure 7: (A) Representative whole-cell K+ currents and corresponding mean ± SEM current 
densities recorded under control conditions (n=15) or 3 hr after exposure (10 min) to 30 µM 
DTDP (n=13), 1 µM CaMKIINtide (n=12), or 30 µM DTDP + 1 µM CaMKIINtide (n=14). (B) 
Representative whole-cell K+ currents and corresponding mean ± SEM current densities recorded 
from untransfected cells without (n=7), or with 30 µM DTDP (n=8), and CaMKIIK42R-
expressing cells without (n=10), or with 30 µM DTDP (n=9). Currents were evoked by a series 
of voltage steps from -80 mV to +80 mV in 10 mV increments. To determine current density 
values, steady-state current amplitudes were measured 180 msec after the initiation of the +10 
mV step and normalized to cell capacitance. Calibration: 10 nA, 25 ms; **p<0.01; 
ANOVA/Dunnett. (C) CaMKIIK42R-expressing neurons are resistant to an overnight exposure 
to activated microglia (AMG) when compared to vector-expressing cells. Kainic acid (KA; 1 
mM overnight) was used as an index for non-apoptotic, total neuronal kill (mean ± SEM of a 
single representative experiment performed in quadruplicate. **p<0.01, ***p<0.001, when 
compared to untreated cells from each group; ANOVA/Bonferroni). (Inset) Percent toxicity from 
either AMG or KA exposure for vector-expressing (green) or CaMKIIK42R-expressing (blue) 
neurons (mean ± SEM, n=7; **p<0.01; paired t-test). (D) Pathway illustrating the convergence 
of zinc- and calcium-mediated signaling pathways during oxidative neuronal injury. Oxidant 
exposure leads to simultaneous release of calcium and zinc, with consequent calcium-dependent 
activation of CaMKII, and zinc-dependent phosphorylation of p38 via a 12-LOX-associated 
activation of ASK-1 (Zhang et al., 2004; 2007). These parallel pathways then converge to 
facilitate the association of syntaxin with Kv2.1. 
 
 
 58 
 
 
 
Figure 8: Zinc chelation prevents the DTDP-induced enhancement of K+ currents in neurons 
 
Figure 8. Representative whole-cell K+ currents and corresponding mean ± SEM current 
densities (at +10 mV) recorded after exposure to 3 µM TPEN (n=7) or 3 µM TPEN + 30 µM 
DTDP (n=9). Currents were evoked by a series of voltage steps from -80 mV to +80 mV in 10-
mV increments. Calibration: 10 nA, 25 ms. 
 
 
 
 
 
 
 59 
 
 
Figure 9: CaMKII inhibition prevents DTDP-induced toxicity in neurons 
 
Figure 9. Neurons transfected with either CaMKIIK42R or an empty vector were exposed to 
DTDP (60 µM, 10 min) and viability was assessed 24 h following exposure by using a luciferase 
expression assay (Aras et al., 2008). Mean ± SEM, n=3; *p<0.05; paired t-test. 
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2.5 DISCUSSION 
Defining the specific contributions of calcium and zinc to neuronal injury pathways has been 
hindered by the fact that most, if not all, calcium-binding agents and indicators also effectively 
interact with zinc (Grynkiewicz et al., 1985; Stork and Li, 2006; Smith, 2009; Haase et al., 
2009). While zinc probes that do not appreciably interfere with calcium-mediated signals exist 
(Arslan et al., 1985; Tomat and Lippard, 2010; Radford and Lippard, 2013), and simultaneous 
changes in calcium and zinc have been detected in injured neurons (Sensi et al., 2002; Dietz et 
al., 2009; Medvedeva et al., 2009; Martin et al., 2011), identifying the specific and separate 
downstream signaling cascades activated by each cation has remained elusive. Here, the 
demonstration that intraneuronal calcium rises independently of zinc following an oxidative 
stimulus, and that calcium-dependent CaMKII activity is necessary for the syntaxin-mediated 
regulation of apoptotic Kv2.1-mediated K+ currents, provides a glimpse into the molecular 
underpinning of what are likely to be widespread dual cation regulatory processes in cells. 
CaMKII has been previously implicated in numerous neuronal cell death processes, as 
inhibition of the kinase is neuroprotective in both in vitro and in vivo injury models (Lin et al., 
2004; Vest et al., 2010; Chen et al., 2011; Liu et al., 2012). Nonetheless, as is the case for many 
other signaling kinase systems, CaMKII activity is associated with the regulation of both 
neuroprotective and neurodestructive cellular signaling pathways (Ashpole and Hudmon, 2011; 
Coultrap et al., 2011). Further, CaMKII is a ubiquitous protein found in high concentrations 
throughout the brain (Erondu and Kennedy, 1985). As such, inhibiting kinase activity is likely to 
be a poor candidate approach for translational therapeutic research studies. We show here, 
however, that CaMKII activity is necessary for the syntaxin-dependent, apoptosis-enabling 
enhancement of Kv2.1-mediated K+ current densities following an oxidative insult. CaMKII 
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likely mediates this process via the direct interaction between the kinase and syntaxin (Figure 
4A), a mechanism that may be amenable to manipulation as a novel therapeutic strategy. 
Exactly how CaMKII participates in the syntaxin-dependent, apoptotic exocytotic 
insertion of Kv2.1 channels into the plasma membrane has yet to be resolved. During exocytosis, 
syntaxin transitions from a closed to an open conformation, which can only occur after the linker 
domain of the protein is released from its SNARE-binding H3 domain (Dulubova et al., 1999; 
Misura et al., 2000). Interestingly, not only has CaMKII been shown to bind to the linker domain 
of syntaxin during neuronal exocytosis, but it is also the only known protein to bind to this 
region (Ohyama et al., 2002). Based on our co-immunoprecipitation results, we suggest that the 
enhanced binding of syntaxin to the dual-phosphorylated Kv2.1 is facilitated by the direct 
interaction of functional CaMKII with syntaxin. Moreover, this process may be promoted by the 
recruitment of additional CaMKII to the Kv2.1/syntaxin complex, as our results also suggest.  
Most Kv2.1 channels are typically found in clusters on the somato-dendritic plasma 
membrane (Trimmer, 1991). Although the clustered channels may conduct current poorly 
(O’Connell et al., 2010), these aggregates appear to be the site of surface delivery of additional 
Kv2.1 protein (Deutsch et al., 2012). Therefore, it will be important to establish in future work 
whether stimuli that affect channel clustering (Misonou et al., 2005; Mohapatra et al., 2009) can 
regulate the SNARE-dependent insertion of new channels during apoptosis, as was recently 
evaluated for a stromal cell-derived chemokine (Shepherd et al., 2012). To aid in the resolution 
of these issues, the results presented in this study establish calcium and CaMKII as a critical 
regulator of the injurious, Kv2.1-dependent K+ current increase in neurons. Importantly, we also 
identify an unprecedented cooperative convergence of zinc- and calcium-mediated signaling 
pathways during oxidative neuronal cell death. 
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3.0  SYNTAXIN-BINDING DOMAIN OF KV2.1 IS ESSENTIAL FOR THE 
EXPRESSION OF APOPTOTIC POTASSIUM CURRENTS 
3.1 ABSTRACT 
Intracellular signaling cascades triggered by oxidative injury can lead to upregulation of Kv2.1 
K+ channels at the plasma membrane of dying neurons. Membrane incorporation of new 
channels is necessary for enhanced K+ efflux and the consequent reduction of intracellular K+, 
which facilitates apoptosis. We showed previously that the observed increase in K+ currents is a 
SNARE-mediated process, and that the SNARE protein syntaxin binds directly to Kv2.1 
channels. In the present study, we tested whether disrupting the interaction of Kv2.1 and 
syntaxin promoted the survival of cortical neurons following injury. Syntaxin is known to bind to 
Kv2.1 in a domain comprised of amino acids 411-522 of the channel’s cytoplasmic C-terminus 
(C1a). Here, we show that this domain is required for the apoptotic K+ current enhancement. 
Moreover, expression of an isolated Kv2.1-derived C1a peptide is sufficient to suppress the 
injury-induced increase in currents by interfering with Kv2.1/syntaxin binding. By sub-dividing 
the C1a peptide, we were able to localize the syntaxin binding site on Kv2.1 to the most plasma 
membrane-distal residues of C1a. Importantly, expression of this peptide segment in neurons 
prevented the apoptotic K+ current enhancement and cell death following an oxidative insult, 
without largely impairing baseline K+ currents or normal electrical profiles of neurons. These 
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results establish that binding of syntaxin to Kv2.1 is crucial for the manifestation of oxidant-
induced apoptosis, and thereby suggest a potential new direction for therapeutic intervention in 
the treatment of neurodegenerative disorders. 
3.2 INTRODUCTION 
Potassium is the most abundant intracellular cation in neurons. It is essential for maintaining the 
resting membrane potential and also for regulating cellular volume (Pasantes-Morales et al., 
1993; Yu, 2003). During injury, K+ efflux and intracellular K+ loss critically contribute to the 
apoptotic volume decrease (Bortner et al., 1997; Maeno et al., 2000), a hallmark morphological 
feature of programmed cell death (Kerr et al., 1972). In addition, reduced cytosolic K+ enables 
apoptosis by providing a permissive environment for activation of caspases and nucleases 
(Hughes et al., 1997; Yu et al., 1997). Kv2.1, a voltage-dependent delayed-rectifier K+ channel 
normally involved in the regulation of high-frequency repetitive firing (Pongs, 1999; Du et al., 
2000; Guan et al., 2013), acts as the primary conduit for K+ efflux during apoptotic cell death in 
neocortical and hippocampal neurons (Pal et al., 2003; Shen et al., 2009). This process occurs via 
the N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-dependent 
exocytotic incorporation of new Kv2.1-encoded channels into the plasma membrane of dying 
neurons, measurable as a large enhancement of voltage-dependent K+ currents (McLaughlin et 
al., 2001; Pal et al., 2003, 2006). Importantly, inhibiting any of the upstream signaling events 
leading to the insertion of Kv2.1, or blocking Kv2.1 channel function itself, is neuroprotective 
(Yu et al., 1997; McLaughlin et al., 2001; Pal et al., 2003; Aras and Aizenman, 2011). 
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The SNARE protein syntaxin was previously shown to interact with the most proximal 
region of the Kv2.1 C-terminus, termed C1a, in a process regulating dense-core vesicle-mediated 
exocytosis in PC12 cells and dorsal root ganglion (DRG) neurons (Singer-Lahat et al., 2007, 
2008; Feinshreiber et al., 2010). Further, introduction of an isolated Kv2.1-derived C1a peptide 
disrupted Kv2.1/syntaxin binding and inhibited the physiological consequences of this 
interaction (Singer-Lahat et al., 2007). We recently demonstrated that the association between 
Kv2.1 and syntaxin is enhanced under conditions that lead to apoptosis (McCord and Aizenman, 
2013), suggesting that interfering with this interaction may provide a novel neuroprotective 
therapeutic strategy. In this study we evaluate (1) whether the syntaxin-binding domain of Kv2.1 
is necessary for the apoptotic K+ current enhancement, and (2) if introduction of C1a or sub-
domains of the peptide can prevent the increase in K+ currents and be neuroprotective in vitro. 
3.3 MATERIALS AND METHODS 
Cell Culture and Transfection Procedures. For electrophysiological experiments, mixed 
cortical neuronal/glial cultures were prepared from embryonic day 16 (E16) Sprague–Dawley 
rats (Charles River Laboratories, Wilmington, MA, USA). Cortices were dissociated with 
trypsin, and the resultant cell suspension, adjusted to 670,000 cells per well, was plated on glass 
coverslips in 6-well plates as described previously (Hartnett et al., 1997). Non-neuronal cell 
proliferation was inhibited after two weeks in culture with 1–2 µM cytosine arabinoside, and 
cultures utilized at three to four weeks in vitro. For neuronal transfection, cells were treated for 
five hours in serum-free medium with 2 µL Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 50 
µL Optimem (GIBCO, Grand Island, NY), and 1.5 µg DNA per well. For Chinese hamster ovary 
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(CHO) cell transfections, cells were plated on coverslips in 24-well plates at a density of 5.6 x 
104 cells per well for electrophysiological measurements or in 100 mm dishes at a density of 1.7 
x 106 cells per dish for biochemical studies. Cells were treated for 3-4 hours in serum-free 
medium with a total of 1.2 µL Lipofectamine and 0.28 µg DNA per well for electrophysiology, 
or 55.1 µL Lipofectamine and 7.33 µg DNA per dish for biochemistry. Following transfection, 
cells were maintained in F12 medium containing fetal bovine serum at 37°C, 5% CO2 for 24 
hours prior to experimentation. 
Drug Treatments and Antibodies. The apoptotic stimulus for electrophysiological 
experiments was 10 minute exposure to 30 µM 2,2’-dithiodipyridine (DTDP) at 37°C, 5% CO2. 
The DTDP-containing solution was removed prior to three-hour incubation in fresh medium 
containing 10 µM butoxy-carbonyl-aspartate-fluoromethyl ketone (BAF), a cysteine protease 
inhibitor that maintains cell viability without affecting K+ currents. Antibodies were purchased 
from the following suppliers: rabbit anti-syntaxin from Abcam (Cambridge, MA); mouse anti-
syntaxin from Millipore (Temecula, CA); mouse anti-Kv2.1 from NeuroMab (Davis, CA).  
Electrophysiological Measurements. Current recordings were performed on eGFP-
positive co-transfected neurons or CHO cells using the whole-cell patch clamp configuration 
technique as described previously (McLaughlin et al., 2001). The intracellular (electrode) 
solution contained (in mM): 100 K-gluconate, 11 EGTA, 10 KCl, 1 MgCl2, 1 CaCl2 x 2H2O, 10 
HEPES; pH adjusted to 7.2 with concentrated KOH; 2.2 ATP and 0.33 GTP were added and the 
osmolarity was adjusted to 280 mOsm with sucrose. The extracellular solution contained (in 
mM): 115 NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 D-glucose; 0.25 µM tetrodotoxin; pH 
adjusted to 7.2. Measurements were obtained under whole-cell voltage clamp with an Axopatch-
1D amplifier and pClamp software (Molecular Devices, Sunnyvale, CA), using 2-3 MΩ 
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recording electrodes. Electrodes were pulled from 1.5 mm borosilicate glass (Warner 
Instruments, Hamden, CT) with a model P-97 mechanical pipette puller (Sutter Instruments, 
Novato, CA). Series resistance was partially compensated (80%) in all cases. Currents were 
filtered at 2 kHz and digitized at 10 kHz with a Digidata 1440A Digitizer (Molecular Devices). 
K+ currents were evoked with incremental 10 mV voltage steps to +80 mV from a holding 
potential of –80 mV. To determine current density values, steady-state current amplitudes were 
measured 180 msec after the initiation of the +10 mV step and normalized to cell capacitance. 
For current clamp experiments, the intracellular (electrode) solution contained (in mM): 94 K-
gluconate, 30 KCl, 10 phosphocreatine di-tris salt, 10 HEPES, 0.2 EGTA, 4 ATP, 0.3 GTP; pH 
adjusted to 7.3 with concentrated KOH. The extracellular solution contained (in mM): 146 NaCl, 
7.8 glucose, 20 HEPES, 4.7 KCl, 0.6 MgSO4, 1.6 NaHCO3, 0.13 NaH2PO4, 2.5 CaCl2; pH 
adjusted to 7.3 with concentrated KOH. Measurements were performed at room temperature with 
an Axoclamp 2B amplifier and G-clamp 2.2 software (Kullmann et al., 2004). Voltage responses 
were induced with 1 s current steps ranging from − 120 pA to 120 pA. Virtual excitatory 
synapses were implemented under dynamic clamp according to gsyn(t)=k*t*exp(-t / tau) with 
tau=1.5 ms and Erev=0 mV. By repeatedly adjusting the scaling factor k, an automated binary 
search algorithm determined threshold synaptic conductance (thresh-gsyn), the conductance 
required to reach firing threshold (Kullmann et al., 2004). 
Immunoprecipitation. Protein was harvested by washing cell culture dishes with ice 
cold PBS followed by a short incubation with 1% 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS) buffer. Protein A/G agarose bead slurry (Santa Cruz, Dallas, TX) 
was added to the samples and rocked at 4°C for 1 hour in order to preclear non-specific protein 
binding. Samples were then incubated overnight at 4°C with the appropriate 
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immunoprecipitating antibodies. Following another incubation with the bead slurry, the protein 
samples were prepared/denatured by the addition of sample preparation buffer (625 mM Tris, 
25% glycerol, 2% SDS, 0.01% bromophenol blue and 5% β -mercaptoethanol) and heated at 
95°C for 5 min prior to SDS-PAGE gel electrophoresis and immunoblotting. 
Electrophoresis and Immunoblotting. Protein samples from equal amounts of cell 
lysate were separated on 10% sodium dodecyl sulfate (SDS) polyacrylamide gels by 
electrophoresis using the Mini Protean 3 System (Bio-Rad, Hercules, CA). Separated protein 
bands were transferred onto 0.2 µm nitrocellulose membranes (Bio-Rad), blocked with 1% 
Bovine Serum Albumin (BSA) in PBS with 0.05% Tween 20 (PBST) at room temperature for 1 
hour, and probed with appropriate primary antibodies diluted in PBST. Blots were then 
incubated with infrared fluorescent goat secondary antibodies at room temperature for 1 hour, 
visualized using the Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE), and 
quantified using infrared fluorimetry. 
Viability Assays. Viability of transfected neurons was assessed by cell counts of GFP+ 
cells. Twenty-four hours after transfection with eGFP in the absence or presence of C1a441-522, 
cultures were treated overnight with either vehicle or microglia (50,000 cells/mL) 
(Cheepsunthorn et al., 2001) plated directly on top of neurons and activated by interferon-γ (IFN-
γ) and lipopolysaccharide (LPS) (Knoch et al., 2008). The following day, cells were preserved 
using 4% paraformaldehyde as reported previously (Aras et al., 2008). GFP+ cells were counted 
in 20 random areas per coverslip using a 20X objective. Coverslips were chosen at random by 
the person performing the cell counts. Experiments were performed in three separate culture 
dates, with three coverslips per condition, per experiment. 
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3.4 RESULTS 
3.4.1 Syntaxin-interacting domain of Kv2.1 is required for apoptotic K+ enhancement 
The most proximal ~110 amino acids of the C-terminus of Kv2.1, corresponding to amino acids 
411-522 of the rat protein sequence, contain the channel’s syntaxin binding site (C1a; Tsuk et al., 
2005). Previous studies in DRG neurons and Xenopus oocytes demonstrated that overexpression 
of a Kv2.1 channel mutant lacking its C1a domain (Kv2.1ΔC1a) results in a marked reduction of 
co-immunoprecipitation between syntaxin and Kv2.1, as well as an inhibition of Kv2.1-mediated 
exocytosis (Singer-Lahat et al., 2007; Feinshreiber et al., 2010). As syntaxin is also involved in 
the apoptotic regulation of Kv2.1-mediated K+ currents (Pal et al., 2006), we first investigated 
whether the C1a region of Kv2.1 was required for this process. To explore this possibility, we 
utilized Chinese hamster ovary (CHO) cells, a recombinant expression system that lacks 
endogenous voltage-gated K+ channels (Yu and Kerchner, 1998), yet has all the cell signaling 
components required to produce an apoptotic current enhancement in Kv2.1-transfected cells 
(Pal et al., 2003). CHO cells expressing either wild-type (WT) Kv2.1, Kv2.1ΔC1a, or a 1:1 ratio 
of Kv2.1 and Kv2.1ΔC1a were subjected to a 10-minute exposure to 30 µM 2,2’-dithiodipyridine 
(DTDP), a thiol oxidant that initiates a zinc- and calcium-dependent signaling cascade 
responsible for the enhancement of Kv2.1 K+ currents observed during apoptosis (McLaughlin et 
al., 2001; McCord and Aizenman, 2013). DTDP treatment was followed by 3-hour maintenance 
in butoxy-carbonyl-aspartate-fluoromethyl ketone (BAF; 10 µM), a broad-spectrum protease 
inhibitor used during recording for its ability to prevent apoptosis downstream of the K+ current 
enhancement (McLaughlin et al., 2001). We found that the DTDP-induced increase in K+ 
currents observed in Kv2.1-expressing CHO cells was absent in cells expressing Kv2.1ΔC1a, 
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suggesting that syntaxin binding to Kv2.1 is an integral component of the machinery mediating 
insertion of new channels into the plasma membrane during oxidative injury. Further, cells 
transfected with a 1:1 ratio of Kv2.1 and Kv2.1ΔC1a plasmids were also refractory to the actions 
of DTDP, demonstrating that even when WT Kv2.1 is present, expression of the mutant channel 
is sufficient to block the effect of the oxidant on the apoptotic increase in Kv2.1-mediated K+ 
currents (Figure 10A).  Importantly, cells expressing the mutant channel exhibited K+ currents 
that appeared indistinguishable from WT Kv2.1-mediated currents (Figure 10B), indicating that 
normal trafficking and expression of this channel is not dependent on the cytoplasmic C1a 
region, as shown previously (Singer-Lahat et al., 2007). 
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Figure 10: The syntaxin-binding C1a domain of Kv2.1 is required for expression of the apoptotic K+ 
current enhancement 
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Figure 10. (A) Representative whole-cell K+ currents and pooled mean ± SEM current densities 
recorded from Kv2.1-expressing CHO cells without (n=19) or with (n=11) 30 µM DTDP, 
Kv2.1ΔC1a-expressing CHO cells without (n=10) or with (n=10) 30 µM DTDP, or CHO cells 
expressing a 1:1 ratio of Kv2.1 and Kv2.1ΔC1a without (n=9) or with (n=16) 30 µM DTDP. 
Results show that the increase in K+ currents triggered by DTDP is suppressed in CHO cells 
expressing Kv2.1ΔC1a. Currents were evoked by a series voltage steps from -80 mV to +80 mV 
in 10 mV increments. To determine current density values, steady-state current amplitudes were 
measured 180 msec after the initiation of the +10 mV step and normalized to cell capacitance. 
Scale bars: 3 nA, 25 msec; **p<0.01, ANOVA/Dunnett. (B) Mean ± SEM IV curves of CHO 
cells expressing Kv2.1 or Kv2.1ΔC1a show that upon depolarization, Kv2.1 mutants lacking 
their C1a domain exhibit similar K+ currents as WT Kv2.1 channels. 
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3.4.2 Kv2.1-derived syntaxin-binding peptide blocks oxidant-induced increase in K+ 
currents 
Incubation with a Kv2.1-derived GST-fusion C1a peptide prevents the binding of syntaxin to 
endogenous Kv2.1 in PC12 cells (Singer-Lahat et al., 2008). Thus, we investigated whether 
expression of C1a in cortical neurons was sufficient to prevent the increase in Kv2.1 K+ currents 
triggered by exposure to an oxidative insult. We found that unlike cells expressing an empty 
vector, those transfected with a C1a-expressing plasmid failed to exhibit the enhanced K+ current 
densities normally elicited by DTDP (Figure 11A). Notably, C1a had no effect on non-apoptotic, 
basal delayed-rectifier K+ currents (Figure 11B), again suggesting that the interaction of syntaxin 
with the C1a region of native Kv2.1 channels is important for their apoptotic regulation, but may 
not be critical for their steady state expression. 
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Figure 11: C1a expression blocks the increase in oxidant-induced K+ currents normally observed 
following DTDP exposure 
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Figure 11. (A) Representative whole-cell K+ currents and pooled mean ± SEM current densities 
recorded from untransfected neurons without (n=10) or with (n=8) 30 µM DTDP, and from C1a-
expressing neurons without (n=8) or with (n=9) 30 µM DTDP. Currents were evoked by a series 
voltage steps from -80 mV to +80 mV in 10 mV increments. To determine current density 
values, steady-state current amplitudes were measured 180 msec after the initiation of the +10 
mV step and normalized to cell capacitance. Scale bars: 5 nA, 25 msec; **p<0.01, 
ANOVA/Dunnett. (B) Mean ± SEM IV curves of untransfected and C1a-expressing neurons 
demonstrate that the peptide does not significantly alter K+ currents when compared to control 
cells. 
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3.4.3 Refining the syntaxin-interacting region within C1a 
After establishing that C1a effectively precluded the oxidant-induced K+ current increase in 
neurons, we sought to identify the sub-domains within C1a that could retain the ability to disrupt 
Kv2.1/syntaxin binding. We first divided C1a into overlapping proximal and distal segments, 
hereafter referred to as C1a411-472 and C1a441-522, respectively. We then performed co-
immunoprecipitation experiments to compare the ability of C1a and the smaller segments to 
displace Kv2.1 from syntaxin. Syntaxin immunoprecipitates of protein samples obtained from 
CHO cells transfected with a syntaxin-expressing plasmid, and co-transfected with Kv2.1 
together with C1a, C1a411-472, or C1a441-522, were probed for Kv2.1. We found that both C1a and 
the distal segment, C1a441-522, inhibited Kv2.1/syntaxin binding, while the proximal segment, 
C1a411-472, did not (Figure 12A). These results reveal that syntaxin binds to Kv2.1 in the more 
distal portion of the C1a domain of the channel’s C-terminus. In subsequent experiments, we 
found that similar to C1a411-472, the overlapping middle segment, C1a441-472, had no effect on 
syntaxin’s ability to bind to Kv2.1 (mean ± SEM ratio of Kv2.1 to syntaxin: baseline=0.24±0.08, 
C1a441-472=0.25±0.1; n=3), suggesting that the syntaxin binding site on Kv2.1 is most likely 
found within residues 472-522 of C1a.  
We previously showed that in CHO cells, overexpression of Src kinase, which induces 
phosphorylation of two Kv2.1 residues required for apoptosis, enhances the binding of Kv2.1 to 
syntaxin (McCord and Aizenman, 2013). Therefore, we evaluated whether C1a441-522 also 
retained the ability to displace Kv2.1 from syntaxin under these conditions, which was indeed the 
case (Figure 12B). 
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Figure 12: Kv2.1/syntaxin binding is disrupted by C1a peptides 
 
Figure 12. (A) Representative co-immunoprecipitation and quantified results from syntaxin-
expressing CHO cells co-transfected with Kv2.1, in addition to C1a, C1a411-472, or C1a441-522. 
Following syntaxin immunoprecipitation, blots were probed with antibodies against Kv2.1 or 
syntaxin (n=6; *p<0.05, ANOVA/Bonferroni). (B) C1a441-522 prevents Kv2.1/syntaxin binding in 
the presence of Src kinase, which was previously shown to enhance this interaction (McCord and 
Aizenman, 2013). Representative co-immunoprecipitation and quantified results from syntaxin-
expressing CHO cells co-transfected with Kv2.1 and Src in the absence or presence of C1a441-522. 
Following syntaxin immunoprecipitation, blots were probed with antibodies against Kv2.1 or 
syntaxin (n=6; *p<0.05, paired t-test). 
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3.4.4 C1a441-522 blocks K+ current enhancement in CHO cells and is neuroprotective 
Once we had established that both C1a and C1a441-522 were able to disrupt binding of syntaxin to 
Kv2.1, we evaluated whether expression of C1a and C1a441-522 was also able to prevent the 
apoptotic K+ current enhancement. To investigate this, we used CHO cells expressing a pseudo-
phosphorylated Kv2.1 channel mutant, Kv2.1S800E, which exhibits an innate, phosphorylation-
independent increase in K+ current densities that mimics the enhanced currents observed in 
apoptogen-exposed, WT Kv2.1-expressing cells (Redman et al., 2007). CHO cells were 
transfected with WT Kv2.1 or Kv2.1S800E in the absence or presence of either C1a or C1a441-
522. Similar to what was observed in DTDP-treated, C1a-expressing neurons, co-transfection with 
C1a suppressed the enhanced K+ currents observed in Kv2.1S800E-expressing CHO cells. 
Importantly, C1a441-522 also blocked the increase in currents produced by the S800E channel 
mutant (Figure 13), further indicating that syntaxin binds to Kv2.1 within the most distal region 
of C1a.  
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Figure 13: C1a and C1a441-522 block K+ current enhancement in CHO cells 
 
Figure 13. Representative whole-cell K+ currents and pooled mean ± SEM current densities 
recorded from CHO cells expressing Kv2.1 (n=14), Kv2.1S800E (n=11), Kv2.1S800E + C1a 
(n=16) or Kv2.1S800E + C1a441-522 (n=14). Currents were evoked by a series voltage steps from -
80 mV to +80 mV in 10 mV increments. To determine current density values, steady-state 
current amplitudes were measured 180 msec after the initiation of the +10 mV step and 
normalized to cell capacitance. Scale bars: 5 nA, 25 msec; **p<0.01, ANOVA/Dunnett. 
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We next evaluated whether C1a441-522 was sufficient to protect neurons against oxidative 
injury. Cells expressing C1a441-522 or an empty vector were exposed to activated microglia, a 
known inducer of Kv2.1-dependent neuronal cell death via peroxynitrite production and 
intraneuronal zinc liberation (Knoch et al., 2008). While microglia reduced viability of vector-
expressing cells by nearly 40%, there was no detrimental effect on neurons expressing C1a441-522 
(Figure 14). Finally, in a series of current-clamp experiments, we found that vector- and C1a441-
522-expressing neurons showed no differences in resting membrane potential, input resistance, or 
threshold synaptic conductance (Figure 15A). We did, however, observe a small but significant 
increase in firing frequency as a function of depolarizing current in C1a441-522-expressing 
neurons, suggesting that C1a441-522 may have a minimal effect on a neuron’s propensity for firing 
action potentials (Figure 15B). Overall, however, the expression of C1a441-522 was relatively 
innocuous to neurons. Taken together, these findings suggest that targeting the interaction 
between Kv2.1 and syntaxin may offer a novel therapeutic strategy in the prevention of 
neurodegeneration that, at least under relatively acute conditions, does not substantially affect 
neuronal electrophysiological properties. 
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Figure 14: C1a441-522 protects against apoptotic cell death in cortical neurons 
 
Figure 14. Cell counts reveal that unlike vector-expressing neurons, those expressing C1a441-522 
are resistant to overnight exposure to activated microglia, a known inducer of Kv2.1-dependent 
neuronal cell death (Knoch et al., 2008). Mean ± SEM counts of GFP+ cells from three 
independent experiments; *p<0.05, paired t-test. 
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Figure 15: C1a441-522 has minimal effect on electrical properties of neurons 
 
Figure 15. (A) Resting membrane potential (Vm) and input resistance (Rin) were measured under 
current clamp, and threshold synaptic conductance (Thresh-gsyn) was measured under dynamic 
clamp in neurons expressing an empty vector or C1a441-522 (mean ± SEM; n=23-28 cells per 
group). (B) Repetitive firing was recorded in vector- or C1a441-522-expressing neurons using 1 sec 
depolarization current steps of increasing amplitude from 15-120 pA. Representative traces of 
neurons from each group at three depolarizing currents, and mean ± SEM frequency-current 
relationships at eight separate currents (*p<0.05, t-test between vector- and C1a441-522-expressing 
neurons; n=23-28 cells per group. Scale bars: 20 mV, 500 msec). Experiments completed by 
Paul Kullmann, PhD. 
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3.5 DISCUSSION 
The findings presented here characterize a cytoplasmic domain within the delayed-rectifier 
Kv2.1-encoded K+ channel that is critical for the expression of neuronal apoptosis. We show that 
Kv2.1 enables cell death through its direct interaction with syntaxin, which promotes the 
enhancement of K+ currents and cytoplasmic K+ loss normally observed following apoptotic 
injury (Bortner et al., 1997; Yu et al., 1997; Pal et al., 2003). Importantly, disrupting 
Kv2.1/syntaxin binding using a plasmid encoding the cytoplasmic Kv2.1 domain C1a441-522 
prevented the K+ current enhancement and was neuroprotective without substantially affecting 
basal K+ currents or the electrical behavior of cortical neurons. These results suggest that the 
processes underlying the membrane insertion of Kv2.1 during apoptosis (Pal et al., 2006) may be 
distinct from channel trafficking under non-injurious conditions. 
Kv2.1 channels have historically been recognized as regulators of neuronal membrane 
potential due to their ability to conduct K+, especially during periods of high-frequency firing 
(Du et al., 2000; Guan et al., 2013). However, it is now becoming evident that these channels 
actually play a much more widespread role in cells than initially thought. In various cell types 
including PC12s, pancreatic β-cells, and DRG neurons, Kv2.1 has been shown to facilitate 
exocytosis in a process that occurs independently of the channel’s ability to conduct K+ (Singer-
Lahat et al., 2007; Feinshreiber et al., 2010; Dai et al., 2012). Further, a direct association 
between syntaxin and the C1a domain of the channel regulated Kv2.1 in its exocytosis-associated 
function, and disrupting this interaction using the C1a peptide inhibited release (Singer-Lahat et 
al., 2007, 2008). Together with our findings, these results reveal that Kv2.1/syntaxin binding is a 
dynamic, highly regulated process, the consequence of which is dictated by the cellular context 
and function for which the channels are required. 
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Other lines of evidence also support a context-dependent role of Kv2.1. In neurons and 
transfected HEK293 cells, Kv2.1 channels residing in the plasma membrane have been shown to 
localize either to dense, ~2 micron-sized clusters, or to a non-clustered formation spread more 
diffusely across the cell surface (Trimmer, 1991; Tamkun et al., 2007; O’Connell et al., 2010). 
Interestingly, in addition to having distinct localizations, these two populations of channels also 
have unique functions. Specifically, it was shown that channels in a clustered pattern may not 
actually conduct K+, and that it is the unclustered population that is responsible for the 
measureable K+ currents observed in electrophysiological recordings (O’Connell et al., 2010). 
More recently, the ability to conduct of Kv2.1 to K+ was shown to negatively correlate with 
plasma membrane channel density regardless of channel localization, although this study was 
performed in a recombinant expression system, and this correlation has not yet been confirmed 
in neurons (Fox et al., 2013). Instead, the clustered channels act as a platform for exo- and 
endocytosis of new Kv2.1 channels. Moreover, it was reported that in addition to Kv2.1, another 
member of the Kv channel family, Kv1.4, was also exocytosed within Kv2.1 clusters, suggesting 
that these regions may act as specialized membrane insertion centers for a number of proteins 
(Deutsch et al., 2012). While these findings lend further support for a role of Kv2.1 in 
exocytosis, work to determine the specific contribution of SNAREs in this setting has yet to be 
undertaken.  
Given the multifaceted nature of Kv2.1 channels in various cellular settings, the question 
now arises as to which of these different functions underlie the pro-apoptotic insertion of 
channels during oxidative injury. It appears that in this capacity, Kv2.1 may function both as a 
facilitator of channel exocytosis and as an ion conductor. Namely, since clustered channels were 
shown to be a platform for insertion (Deutsch et al., 2012), it is possible that during apoptosis, 
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pre-existing, clustered channels are responsible for promoting the exocytosis of new Kv2.1 
channels, with the newly inserted channels then generating the enhanced K+ currents observed 
during cell death. Thus, if syntaxin binds to the clustered population of channels regulating 
exocytosis, it is possible that during apoptosis, in addition to preventing the insertion of new 
Kv2.1 channels, disrupting Kv2.1/syntaxin binding with C1a441-522 could also potentially hinder 
exocytosis of other proteins such as Kv1.4. We did observe a small but significant increase in 
firing frequency as a function of current in C1a441-522-transfected neurons, suggesting that C1a441-
522 may, to a minimal extent, affect normal trafficking of Kv2.1 or other Kv channels involved in 
regulating excitability. However, the fact that C1a441-522 had no effect on basal K+ currents, 
resting membrane potential, input resistance, or threshold synaptic conductance, and that C1a441-
522-expressing neurons remained viable, indicates that the peptide does not adversely affect 
normal Kv2.1-mediated processes. Moreover, previous studies have demonstrated that in 
addition to the C1a domain, secondary syntaxin binding sites may also exist on Kv2.1 (Leung et 
al., 2003), suggesting that SNARE-dependent processes may be in place even without C1a. 
While further studies are required to fully elucidate the role of Kv2.1/syntaxin binding in 
oxidative neuronal injury, the ability of C1a441-522 to render neurons completely viable in the face 
of a lethal injurious stimulus offers a promising new approach to the treatment of neurological 
conditions associated with apoptotic injury. 
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4.0  GENERAL DISCUSSION 
Although a number of studies have reported a simultaneous increase in intracellular zinc and 
calcium during neuronal injury, whether the metals work in concert to mediate cell death had 
heretofore remained unclear (Sensi et al., 2002; Vander Jagt et al., 2009; Medvedeva et al., 
2009). As dyshomeostasis of either calcium or zinc can have extremely adverse effects on 
neurons (Choi, 1995; Sensi et al., 2011), advancing our understanding of how these two cations 
cooperatively regulate neuronal injury could lead to the development of strategies to halt the 
toxic signaling cascades triggered by the metals before neurons succumb to apoptosis. The 
findings presented in this dissertation establish a role for calcium and its downstream target 
CaMKII in a previously characterized zinc- and Kv2.1-dependent apoptosis pathway (Aras and 
Aizenman, 2011). Namely, CaMKII was shown to be indispensible for the SNARE-mediated 
plasma membrane insertion of Kv2.1; however, several questions remain regarding the precise 
details underlying the action of the kinase, which will be addressed below. Additionally, this 
work also serves to enhance our knowledge of the mechanism responsible for the plasma 
membrane insertion of Kv2.1 channels requisite for neuronal apoptosis. As injurious K+ efflux 
during apoptosis in cortical neurons occurs primarily through Kv2.1 (Pal et al., 2003), 
identifying techniques to selectively inhibit the pro-apoptotic function of these channels could 
provide a novel opportunity for the prevention of cell death during disorders related to oxidative 
stress. However, as will be discussed here, the physiological and pathophysiological roles of 
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neuronal Kv2.1 appear to be much more complex than initially realized. This discussion will, in 
part, attempt to unify studies describing the disparate putative cellular roles of Kv2.1, primarily 
during neuronal injury, in an attempt to convey the notion that Kv2.1 exists along a spectrum of 
specific functional roles dictated by the particular status of the channel (e.g. localization, 
phosphorylation, etc.), temporal profile of injury and overall cellular environment, as well as the 
precise upstream signals that converge on the channel. 
4.1 ROLE OF CAMKII IN OXIDATIVE NEURONAL INJURY 
CaMKII is a ubiquitously expressed protein kinase represented by four isoforms: α, β, γ, and δ. 
α and β, the isoforms constituting neuronal CaMKII, represent up to 2% of the total protein in 
certain brain areas such as the hippocampus, and up to 1% in the forebrain (Erondu and 
Kennedy, 1985). CaMKII exists as holoenzymes containing ~8-14 subunits, each comprised of a 
catalytic, regulatory, and association domain. The kinase is normally rendered inactive through 
inhibition of the catalytic domain by the regulatory domain, which obstructs both the ATP- and 
substrate-binding sites; activation of CaMKII occurs as the result of calcium/calmodulin-
dependent displacement of the regulatory domain from the catalytic domain, and subsequent 
intersubunit autophosphorylation of the Thr286 residue.  
Although CaMKII has previously been implicated in oxidant-induced neuronal injury, the 
results presented in Chapter 2 were the first to demonstrate a role for the kinase in zinc- and 
Kv2.1-dependent apoptosis. Still, while this work established CaMKII as a regulator of Kv2.1 
activity through its direct interaction with syntaxin, several questions remain regarding the 
details of the kinase’s involvement in the cell death-enabling pathway triggered by oxidants. 
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Previous studies carried out in cardiac tissue have found increased CaMKIIδ expression during 
arrthymias and heart failure (Hoch et al., 1998; Ai et al., 2005; Kushnir et al., 2010; Respress et 
al., 2013), a consequence of which appears to be direct phosphorylation of RyRs by CaMKII, 
leading to calcium release and subsequent injurious calcium dyshomeostasis. Based on these 
findings, it is possible that during zinc-mediated oxidative neuronal injury, in addition to 
interacting with syntaxin downstream of ER calcium release, CaMKII could also contribute to 
the ER calcium release process itself. If CaMKII does mediate the initial release of calcium from 
the ER, it is not clear if a distinct source of calcium would activate the kinase, or if once 
activated, CaMKII would then target ER RyRs to trigger further calcium release. However, since 
all of the calcium released during this process originated from the ER (Figure 1B), it is more 
likely that CaMKII activation would occur exclusively downstream of the initial ER calcium 
release. Still, although CaMKII-mediated phosphorylation of RyRs has been observed in the 
heart, it has not been established if this same process occurs in the brain. Further, while 
activation of CaMKII by methionine oxidation appears to be involved in the kinase’s regulation 
of RyRs (Ho et al., 2013), and cardiac function in general (Erickson et al., 2008; Purohit et al., 
2013), this mechanism of activation of CaMKII does not occur during oxidative neuronal injury 
(Figure 1D). Indeed, oxidation-dependent CaMKII activation has only been observed in heart 
cells, and it has yet to be established if a similar process occurs with neuronal CaMKII. 
Another question that has yet to be answered is precisely how CaMKII modulates 
syntaxin, and how inhibition of the kinase exerts its protective effect. CaMKII physically 
interacts with syntaxin (Figure 4A), and transfection with a kinase-inactive CaMKIIK42R 
mutant prevents Kv2.1/syntaxin binding (Figure 4C), the apoptotic enhancement of Kv2.1-
mediated K+ currents, and downstream cell death (Figure 7). Thus, because the kinase-inactive 
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mutant lacks the ability to phosphorylate its substrate, it is likely that prior to apoptosis, CaMKII 
regulates syntaxin via phosphorylation, although the functional consequences of this 
phosphorylation event are not yet clear. Previously, it was hypothesized that binding of CaMKII 
to syntaxin could induce a conformational change to facilitate the conversion of syntaxin from a 
closed to an open form required for subsequent SNARE binding (Ohyama et al., 2002; Nomura 
et al., 2003). However, more recent evidence has shown that SNARE complex formation can 
occur in the absence of CaMKII/syntaxin binding, although vesicle recycling and vesicle density 
were reduced when this interaction was attenuated (Watanabe et al., 2013). Thus, it is possible 
that inhibition of Kv2.1/syntaxin binding by expression of CaMKIIK42R prevents the Kv2.1-
mediated K+ current enhancement by affecting the availability of Kv2.1-containing vesicles at 
the plasma membrane. Clearly, further research is needed to fully elucidate the molecular 
mechanism by which CaMKII regulates syntaxin. 
While the kinase-inactive CaMKIIK42R mutant would be unable to phosphorylate 
syntaxin, it is not clear if the mutation also prevents CaMKII from physically interacting with 
syntaxin, or if this process remains intact. Based on previous reports, though, it appears as 
though it is binding of calcium/calmodulin, and not ATP, that dictates CaMKII trafficking and 
interaction with other proteins. Specifically, CaMKII containing the K42R mutation was found 
to retain the ability to translocate to the post-synaptic density, while disruption of calmodulin 
binding prevented this process (Shen and Meyer, 1999). Further, in hippocampal neurons, 
CaMKII was shown to interact with NR2B subunit of the NMDA receptor in the even absence of 
ATP, as long as calcium/calmodulin was present (Bayer et al., 2001). Therefore, it is a definite 
possibility that in our studies, CaMKII expressing the K42R mutation still interacts with syntaxin 
despite its inability to phosphorylate its target. 
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Another question that has yet to be addressed is how CaMKII is inactivated during 
Kv2.1-mediated apoptosis. Dephosphorylation of CaMKII residue Thr286 inactivates the kinase, 
and dephosphorylation of this site has been found to be mediated primarily by protein 
phosphatase 2A (PP2A; Strack et al., 1997). Interestingly, zinc has been shown to regulate Src-
dependent inactivation of neuronal PP2A (Sun, et al., 2012; Xiong et al., 2013). Thus, while 
CaMKII activation is not affected by zinc (Figure 1C), it is possible that the increase in 
intracellular zinc observed during apoptotic injury serves to prolong CaMKII activity by 
inhibiting PP2A, thereby preventing the inactivation of the kinase. Biochemical experiments 
determining the effect of the zinc chelator TPEN on oxidant-induced CaMKII Thr286 
phosphorylation at multiple time points may clarify the effect of the metal on CaMKII 
inactivation. 
4.2 EFFECT OF KV2.1 PHOSPHORYLATION DURING APOPTOSIS 
Dual phosphorylation of Kv2.1 residues Y124 and S800 is necessary to elicit the apoptotic 
increase in K+ currents and downstream cell death (Redman et al., 2009). Findings in Chapter 3 
demonstrated that Kv2.1 phosphorylation also promotes the binding of syntaxin to Kv2.1 prior to 
apoptosis. Questions remain regarding the specific function of phosphorylation of residues Y124 
and S800, and on which population of channels this phosphorylation occurs. Because Kv2.1 can 
bind to syntaxin under basal conditions (Singer-Lahat, 2007), it is unlikely that phosphorylation 
of S800 is directly responsible for this interaction, although basal S800 phosphorylation can also 
been observed (Fig. 6). Channels expressing a non-phosphorylatable S800A mutation do not 
exhibit apoptotic Kv2.1-mediated K+ currents, yet are still expressed at the plasma membrane 
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and maintain basal K+ currents, suggesting that phosphorylation of this site is not essential for 
normal trafficking of Kv2.1 (Redman et al., 2007). Thus, it is possible that p38 is localized to 
vesicles containing those channels that will be responsible for generating the increased K+ 
currents observed during apoptosis, and that phosphorylation of those channels by p38 triggers 
their delivery to SNARE proteins at the cell surface, which then facilitates the incorporation of 
channels into the plasma membrane. If this were the case, the enhanced binding of Kv2.1 and 
syntaxin induced by phosphorylation of Kv2.1 would likely be the result of an increased 
presence of channels in the vicinity of plasma membrane-bound syntaxin. Presumably then, 
channels lacking the C1a domain (Kv2.1ΔC1a) and exposed to DTDP (Figure 10) are still 
delivered to the plasma membrane, but cannot undergo exocytosis due to an inability to bind to 
syntaxin. Further, since the apoptotic K+ current enhancement was also absent cells expressing 
both WT Kv2.1 and Kv2.1ΔC1a plasmids, it appears that each of the channel’s four subunits 
must contain an intact syntaxin binding site to be involved in the apoptotic current enhancement. 
However, if the Kv2.1ΔC1a mutation prevents the K+ current enhancement directly through the 
inability to bind syntaxin, or if it does so by altering the conformation of the channel and its 
relation to adjacent subunits remains to be established.  
While the work presented in this dissertation firmly demonstrate that Kv2.1/syntaxin 
binding mediates oxidative neuronal apoptosis, precisely how this association contributes to cell 
death is not yet entirely clear. The channel directly interacts with syntaxin in non-injurious 
conditions as well, and it is not known if the consequences of this interaction are different in 
distinct cellular settings. Still, these findings suggest that Kv2.1 is a multifaceted ion channel that 
is dynamically regulated during both health and disease, with the phosphorylation status of the 
channel being an important determinant of its function. Further, and as will be discussed below, 
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it appears that even subtle differences in the cellular environment in which Kv2.1 channels are 
found could result in variable responses from the channel that play an integral role in 
determining the fate of neurons.  
4.3 ROLE OF KV2.1 DURING PERIODS OF PATHOLOGICAL 
HYPEREXCITABILITY 
Kv2.1 is normally maintained in a highly phosphorylated state (Park et al., 2006), localized in 
part to dense somato-dendritic clusters within the plasma membrane (Trimmer, 1991). Most of 
the channel’s phosphorylation sites are located within the unusually long C-terminus, which 
accounts for more than half (443/853) of the channel’s total amino acid residues. Intriguingly, 
Kv2.1 has a larger C-terminus than any other Kv channel, and it is the region of the channel that 
is most distinct from its closest relative, Kv2.2. This distinctive property of Kv2.1 likely 
contributes to its unique functional role amongst Kv channels. Indeed, phosphorylation of Kv2.1, 
especially in the C-terminus, has been shown to exert significant effects on overall channel 
function (Antonucci et al., 2001; Mohapatra et al., 2007; Redman et al., 2009). 
Conditions of injurious neuronal hyperexcitability, such as epileptic seizures, are marked 
by excessive glutamate and calcium release that can cause excitotoxicity in affected neurons. 
Similar to its effect on physiological high-frequency firing, Kv2.1 has also been shown to 
contribute to the suppression of neuronal excitability under pathological conditions such as 
ischemia, or following exposure to glutamate or kainic acid. The mechanism underlying channel 
modulation within this context involves an increase in intracellular calcium and consequent 
calcineurin phosphatase-dependent dephosphorylation of Kv2.1 at several C-terminal amino acid 
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residues. This change in phosphorylation state triggers a hyperpolarizing shift in the channel’s 
voltage-dependence of activation (with no effect on maximal K+ current densities), and is 
accompanied by a lateral dispersal of channels from clusters into a more diffuse localization. 
These modifications contribute to an increase in Kv2.1 activity, which manifests as a dampened 
response to injurious over-excitation, and thus serves as a putative innate protective mechanism 
within neurons (Misonou et al., 2004; Misonou et al., 2005; Mohapatra et al., 2009). 
Interestingly, while the general mechanism described above underlies Kv2.1 activity 
during over-excitation, certain details of the signaling cascade vary in a stimulus-specific 
manner. Two separate studies conducted by James Trimmer and colleagues demonstrated that 
both exposure to glutamate or kainic acid, and induction of hypoxia/ischemia triggered Kv2.1 
dephosphorylation by calcineurin, a shift in activation voltage, and channel dispersal, which 
together suppressed excitatory activity. Moreover, in both studies, these effects were rapid and 
reversible, suggesting that this is a transient response to short-term changes in overall neural 
activity (Misonou et al., 2004; Misonou et al., 2005). Curiously, though, while both exposure to 
glutamate or kainite, and induction of hypoxia/ischemia led to the aforementioned cellular 
alterations, there were also several modest distinctions between the mechanisms underlying these 
effects. For example, while Kv2.1 modulation by glutamate or kainate relies on the influx of 
extracellular calcium into neurons (Misonou et al., 2004), hypoxia/ischemia-induced channel 
regulation largely depends on calcium release from intracellular stores (most likely 
mitochondria), and is therefore unaffected by chelation of extracellular calcium. Further, Kv2.1 
channel modulation by hypoxia/ischemia is, remarkably, not dependent on glutamate (Misonou 
et al., 2005). Thus, while it appears that Kv2.1 functions primarily as a suppressor of neuronal 
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firing during periods of hyperexcitability, precisely how this effect is achieved appears to be 
quite a nuanced process that depends, at least in part, on the nature of the injurious stimulus. 
4.4 KV2.1-MEDIATED K+ EFFLUX DURING OXIDANT-INDUCED NEURONAL 
APOPTOSIS 
Our understanding of Kv2.1 function is further complicated by the fact that enhanced Kv2.1-
mediated K+ efflux can also facilitate neurotoxicity in models of oxidant-induced apoptosis. As 
described earlier in the dissertation, oxidative injury triggers the incorporation of new Kv2.1 
channels into the plasma membrane, leading to an increase in K+ currents and consequent 
reduction in intracellular K+ that precedes apoptosis. This insertion event is dependent upon the 
phosphorylation of channel residues Y124 and S800 by Src kinase and p38 MAPK, respectively, 
and unlike hyperexcitability, occurs in the absence of changes in channel gating kinetics (Yu et 
al., 1997; Pal et al., 2003; Pal et al., 2006). Interestingly, while several channel residues have 
been shown to be targets of calcineurin dephosphorylation during hyperexcitability, S800 is not 
one of them, and does not appear to play a role in altering channel gating and localization under 
these conditions (Park et al., 2006). In fact, at present, the sole known function of 
phosphorylation of residue S800 is to facilitate the pro-apoptotic introduction of Kv2.1 into the 
plasma membrane, suggesting that this event likely contributes to the functionally distinct role of 
Kv2.1 during apoptosis. Further, the injury-induced increase in Ik is specific to apoptosis, and is 
not observed in neurons undergoing other forms of cell death, such as necrosis (Yu et al., 1997; 
Pal et al., 2003). Thus, Kv2.1 appears to play divergent roles during conditions related to 
hyperexcitability and those involving oxidative apoptosis, a distinction that is dictated in part by 
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the specific phosphorylation state of the channel. However, what other factors contribute to the 
distinct functions assumed by Kv2.1 during different types of neuronal injury is less clear, as 
similar upstream signaling events have been observed during both oxidative injury and 
hyperexcitability. For example, increased intracellular zinc, which is a hallmark of Kv2.1-
dependent apoptosis and is required for the phosphorylation of Y124 and S800 (Aizenman et al., 
2000; Redman et al., 2007; Redman et al., 2009), has also been shown to mediate ischemia-
induced channel dephosphorylation and alterations in gating kinetics (Aras et al., 2009). 
Moreover, intracellular calcium release was recently shown to be a component of oxidant-
induced, Kv2.1-mediated apoptosis (McCord and Aizenman, 2013). 
The uncertainty surrounding the regulation of Kv2.1 was further magnified following a 
recent report demonstrating that the effect of the chemokine stromal cell-derived factor-1 (SDF-
1α) on Kv2.1 depended on exposure time, with short-term exposure inducing changes in Kv2.1 
reminiscent of its function during hyperexcitability, while prolonged exposure led to changes in 
channel activity similar to those observed during oxidative apoptosis. Specifically, acute 
exposure (30 minutes) of cultured hippocampal neurons to SDF-1α led to calcineurin-dependent 
Kv2.1 dephosphorylation, cluster dispersal, and a leftward shift in the voltage-dependence of 
channel activation, all as a means to suppress neuronal activity in order to prevent non-apoptotic 
cell death. Conversely, prolonged exposure (three hours) to SDF-1α led to apoptosis via p38-
dependent Kv2.1 plasma membrane insertion and enhancement of K+ currents (Shepherd et al., 
2012). These findings suggest that Kv2.1 activity initially serves to reduce the extent of non-
apoptotic neuronal cell death; however, presumably after reaching a currently unidentified 
cellular injury threshold, Kv2.1 function shifts to serving in a pro-apoptotic capacity. This 
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phenomenon could be relevant to disorders such as cerebral ischemia, whereby neurons undergo 
either apoptosis or necrosis, depending on the spatial and temporal profile of the initial injury. 
Taken together, it appears that Kv2.1 channels exist along a spectrum of possible 
activities, and how the channel functions is dictated by the type of injury sustained, duration of 
stimulus exposure, the phosphorylation state of the channel, presumably in addition to other 
factors that have yet to be established. What is particularly interesting about this differential 
regulation of the channel is that seemingly minor distinctions—e.g. exposure to the same 
stimulus for 30 minutes versus three hours (Shepherd et al., 2012)—can result in markedly 
different responses from Kv2.1, suggesting that the channel can sense relatively subtle changes 
in cellular state and respond accordingly. As such, a comprehensive understanding of what 
molecular processes underlie Kv2.1 function in various cellular settings will likely by essential 
for the development of successful therapeutic strategies aimed at this channel. 
4.5 KV2.1 MAINTAINS SEVERAL DISTINCT ACTIVITY PROFILES 
Kv2.1 channels thus seem to maintain several activity profiles that are determined by the needs 
of the cell or specific cellular environment at a given time. Recent studies have shown that in 
addition to the population of Kv2.1 localized to clusters, a substantial proportion of channels 
exists in a more diffuse localization, even under basal conditions (Tamkun et al., 2007). 
Interestingly, the clustered population was found to be non-conducting, and instead acted as a 
platform for exocytosis, while the dispersed channels appeared to be responsible for the delayed 
rectifier K+ currents observed in neurons. Thus, it appears that Kv2.1 channels normally maintain 
a dual role as either ion conductors or facilitators of exocytosis, possibly primarily depending on 
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their localization (Profile 1). It is not know what molecular processes underlie the delineation 
between these two functions, but the phosphorylation state of the channel could perhaps play an 
important role.  
During periods of high-frequency firing, both physiological and pathophysiological, the 
clustered population of channels disperses and activation kinetics shift following 
dephosphorylation (Profile 2). Although it is not known if channel dispersal is a cause or effect 
of the change in gating kinetics, declustering may occur to convert some of these channels from 
secretors to K+ conductors to accommodate the change in synaptic activity and prevent over-
excitation. Therefore, channel declustering could signify the shift in the functional balance 
toward ion conduction as a means to maintain cellular homeostasis. Further, it is possible that 
channel declustering also prevents over-excitation by displacing Kv2.1 in order to disable the 
exocytotic machinery and therefore inhibit neurotransmission; however, whether Kv2.1/syntaxin 
binding mediates synaptic vesicle release (versus LDCV release) has yet to be determined 
directly. The mechanism underlying channel dispersal is still unclear, although the 
phosphorylation state of Kv2.1 appears to be an important determinant of function, as variable 
dephosphorylation leads to a graded shift in voltage-dependence of channel activation (Park et 
al., 2006).  This model, however, is complicated by the fact that declustering and concomitant 
changes in channel activation profiles are not reflected by an overall increase in current densities. 
Thus, exactly what population of channels is in a conducting mode or not prior to declustering 
remains to be determined. 
During oxidative injury, Kv2.1 channels adopt a third profile that has been characterized 
by our laboratory, and is marked by the delivery of new channels to the plasma membrane that 
results in increased K+ efflux prior to apoptosis (Profile 3). The effect of oxidative injury on 
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channel localization (clustered or dispersed) is not known, but as speculated in Chapter 3, 
clusters likely remain intact to facilitate the incorporation on new channels into the membrane. 
Kv2.1-mediated K+ efflux and downstream apoptosis has been observed following serum 
deprivation and after exposure to various injurious stimuli including oxidants, activated 
microglia, and staurosporine (Pal et al., 2003; Knoch et al, 2008; Zhou et al., 2012). Therefore, 
adoption of this profile by Kv2.1, which depends on the phosphorylation of channel residues 
Y124 and S800, appears to be common to numerous forms of neuronal injury. 
Recent studies have suggested a fourth possible activity profile for Kv2.1 channels that 
could be relevant to Alzheimer’s disease and other neurodegenerative disorders. In this case, 
oxidation of Kv2.1 causes channel oligomerization through the formation of intersubunit 
disulfide bridges between two N- and C-terminal cysteine residues, C73 and C710. Oxidant-
induced oligomerization triggered ROS production and apoptosis, with these effects being 
blocked in CHO cells expressing a channel mutant (Kv2.1C73A) that is incapable of 
oligomerizing. Interestingly, aged wild-type mice exhibited enhanced Kv2.1 oligomerization, 
and this effect was exacerbated in aged 3xTg-AD transgenic mice. Further, exposure to Aβ led to 
Kv2.1 oligomerization and subsequent apoptosis that was absent in Kv2.1C73A-expressing cells 
(Cotella et al., 2010). The mechanism underlying Kv2.1 oligomerization-induced toxicity was 
later revealed to involve oxidant-induced accumulation of Kv2.1 at the plasma membrane, 
presumably due to an inability of channels internalize properly. The apoptotic effect of channel 
oligomerization was found to be mediated by Src and JNK kinases, and was thought to stem 
from disruption of lipid rafts, with cholesterol supplementation of the rafts conferring an anti-
apoptotic effect (Wu et al., 2013). Of note, Kv2.1 channels were previously found to be localized 
to lipid rafts (Martens et al., 2000; Martens et al., 2001), and disruption of the rafts by prolonged 
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cholesterol depletion triggered a hyperpolarizing shift in the voltage-dependence of channel 
inactivation as well as an increase in channel cluster size (O’Connell and Tamkun, 2005). 
Although Kv2.1 oligomerization does appear to be a consequence of some forms of 
oxidative stress and an important factor in the propagation of Aβ-mediated toxicity, it is too soon 
to conclude that this channel profile is entirely distinct from that adopted during previously 
described forms of oxidative apoptosis (Profile 3), which places phosphorylation-dependent 
Kv2.1 channel upregulation at the plasma membrane as a critical upstream event in apoptosis 
(Pal et al., 2003; Redman et al., 2009). Although the oligomerization model (Profile 4) argues 
that the toxic effect of Kv2.1 actually stems from oligomerization-induced disruption of lipid 
rafts and subsequent Src- and JNK-mediated apoptosis, it is likely that phosphorylation-
dependent and oligomerization-dependent apoptosis are not mutually exclusive, and therefore 
both explanations could be considered to be true. Which activity profile is adopted seems to 
depend on the time course of the injurious sequelae, with oligomerization occurring at earlier 
time points, while channel insertion and apoptotic current expression, allowing for optimal 
caspase activity, occurs much later. 
4.6 LOCATING THE MOLECULAR SWITCH DURING KV2.1-MEDIATED 
APOPTOSIS 
Because the requirements for anti-death versus pro-death Kv2.1 function appear to be discrete, it 
is likely that a specific set of biochemical changes underlie this transition. Presumably, then, a 
clinically effective Kv2.1 channel modulator would need to target events specific to the adoption 
of one channel profile or another. Otherwise, nonspecific Kv2.1 channel modulators used during 
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oxidative injury could have the unwanted side effect of excitotoxicity, while those used during 
disorders of hyperexcitability could result in increased apoptosis. Further, because it appears that 
the activity profile of Kv2.1 channels is determined by a delicate molecular balance within cells, 
use of inhibitors derived from endogenous Kv2.1-regulating mechanisms would likely be the 
best approach to achieving the desired specificity that is lacking in current Kv2.1 channel 
blockers. 
           The findings presented here, in combination with previous work in our laboratory, have 
begun to unravel the molecular mechanisms underlying Kv2.1 channel activity in oxidant-
induced apoptosis. During periods of hyperexcitability, Kv2.1 exerts a protective effect via 
dephosphorylation and consequent hyperpolarization of voltage-dependence of activation, 
leading to decreased firing frequency. These changes presumably occur within Kv2.1 channels 
embedded in the plasma membrane at the time of injury, as glutamate exposure triggered these 
modifications without an effect on the number of channels present at the cell surface (Misonou et 
al., 2004). Conversely, the pro-death function of Kv2.1 seen during oxidative injury occurs as a 
result of new channels being delivered to the plasma membrane (Pal et al., 2006). Thus, while 
some of the upstream components of these signaling pathways are similar, the pool of channels 
exerting the effect on cell survival may in fact be distinct. Therefore, one potential approach to 
minimizing apoptotic K+ efflux without inadvertently inducing excitotoxicity would be to 
impede the delivery of Kv2.1 channels to the plasma membrane by targeting a component of the 
delivery/exocytosis machinery.  
The work presented in Chapter 3 established that the SNARE protein syntaxin binds to 
the C1a domain of Kv2.1 to facilitate the pro-apoptotic plasma membrane insertion of the 
channel. Interruption of this interaction using C1a-derived peptides prevented the K+ current 
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enhancement and downstream apoptosis without substantially affecting basal K+ currents or 
passive electrical properties of neurons. Thus, while syntaxin and Kv2.1 do interact during 
exocytosis in non-apoptotic conditions, acutely disrupting this association does not appear to 
substantially hinder normal Kv2.1 trafficking. Further, CHO cells transiently expressing a Kv2.1 
channel mutant lacking its syntaxin binding site (Kv2.1ΔC1a), and neurons expressing the C1a 
peptide itself exhibited normal basal K+ currents and current-voltage relationships one day post-
transfection. These findings bode well for Kv2.1/syntaxin binding as a potential target for 
therapeutic intervention, although future experiments will be needed to clarify if and how 
disrupting Kv2.1/syntaxin binding affects channel trafficking over time. It is possible that 
syntaxin is abundant enough within neurons that even in the presence of C1a, an unbound 
proportion of the protein would remain able to interact with Kv2.1 to facilitate exocytosis. 
Moreover, because Kv2.1 has been shown to be both a suppressor and promoter of exocytosis in 
different cellular settings (MacDonald et al., 2002; Singer-Lahat et al., 2007), it is not apparent 
how inhibiting the channel during apoptosis would affect release under these conditions. Further, 
it is not known if syntaxin has different affinities for Kv2.1 during apoptosis versus exocytosis, 
although we showed that Kv2.1/syntaxin binding is enhanced when the channel is 
phosphorylated at residues Y124 and S800, suggesting that the interaction is promoted during 
apoptosis. Based on these experiments, it is not clear if channel phosphorylation per se enhances 
Kv2.1/syntaxin binding, or if the increase in binding is simply due to a phosphorylation-induced 
increase in channels at plasma membrane prior to apoptosis, which would bring Kv2.1 in close 
enough proximity to syntaxin for the interaction to take place. Again, future experiments are 
required to fully elucidate this mechanism. 
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4.7 KV2.1 CHANNEL BLOCKERS AS A THERAPEUTIC STRATEGY 
Until now, numerous K+ channel blockers have had success in preventing apoptotic CNS injury 
both in vitro and in vivo (Huang et al., 2001; Wei et al., 2003; Zaks-Makhina et al., 2004; Hu et 
al., 2006).  However, these compounds have not progressed past the level of animal models. One 
reason for this is the lack of specificity of most currently available K+ channel blockers. For 
example, while the compounds TEA, 4-AP, and a number of natural K+ channel blockers such as 
hanatoxin (derived from spider venom) inhibit Kv2.1, they also act on other Kv channels as well 
(Swartz and MacKinnon, 1995; Madeja et al, 2000; Zhang et al., 2003). This is not surprising 
considering the structural similarities between certain Kv channels, particularly in the 
transmembrane domain, which is the target of many K+ channel blockers. Additionally, Kv 
channel modulators can also affect non-Kv channel targets such as Na+, K+-ATPases, NMDA 
receptors, and calcium channels (Eckstein-Ludwig et al., 1998; Wang et al., 2003). As mentioned 
previously, the C-terminus of Kv2.1 has been shown to mediate a number of neuropathological 
conditions, mostly through its dynamic phosphorylation. This domain is relatively unique to the 
Kv2.1 channel, as it displays much less striking sequence homology to its closest relative, Kv2.2, 
than does the rest of the channel. Therefore, disrupting the interaction of Kv2.1 and syntaxin that 
takes place in the channel’s C-terminus, as I have done in my dissertation research, could be a 
promising new direction to take in the development of Kv2.1 channel modulators to protect 
against oxidant-induced apoptosis. 
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